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1  General 
 
Technion Data 
All reactions were carried out in dry glassware under positive pressure of argon.  THF and Et2O were used following purification from a zeolite drying apparatus (Pure-Solv® Purification System; Innovative Technology©).  All Grignard reagents (incl. MeMgBr solution in Et2O purchased from Sigma–Aldrich; others prepared in-house) were titrated with tert-butanol solution in toluene with 1,10-phenanthroline as indicator.  All other chemicals were used as supplied.  Chromatographic separations were performed on Bio-Lab silica gel 60Å (40–63 μm).  Thin–layer chromatography was performed on Merck© TLC Silica gel 60 F254 and visualised by UV (254 nm), KMnO4 and/or phosphomolybdic acid: 1H and 13C NMR spectra were recorded on Bruker© Avance 500, 400, and 300 spectrometers.  Residual solvent peaks were used as internal standards.[1] Chemical shifts are quoted in ppm using the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; qn quintet; sx sextet; non nonet, m multiplet; br, broad; or a combination thereof.  The coupling constants J are measured in Hz. Mass spectra (APCI or ESI) were recorded at the Schulich Faculty of Chemistry, Technion–Israel Institute of Technology. 
Caltech Data 




2  Supplementary Tables 
 











3  Procedures 
3.1  Ynecarbamates 
 
Representative Procedure A [Hsung coupling with cyclic carbamates][5] 
A slurry of ynecarbamate (1.0 equiv), 1-bromoalkyne (1.2 equiv), CuSO4∙5H2O (0.2 equiv) 1,10-phenanthroline monohydrate (0.4 equiv), and K2CO3 (2.0 equiv) in toluene (50–60 mL) was stirred at 70–90 °C for 24 h.  The mixture was cooled to room temperature, diluted with DCM and filtered through silica, washed with DCM, concentrated under reduced pressure and the crude residue was purified by flash chromatography with EtOAc/Hex (1:5) to give the product. 
 
3-(Hex-1-yn-1-yl)oxazolidin-2-one (1a)[5] 







Representative Procedure A.  Prepared from oxazolidin-2-one (3.1075 g, 35.7 mmol, 1.0 equiv) and 1-bromooct-1-yne (8.097 g, 42.8 mmol, 1.2 equiv) using K2CO3 (9.858 g. 71.4 mmol, 2.0 equiv), CuSO4·5H2O (1.782 g, 7.1 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (2.829 g, 14.3 mmol, 0.4 equiv) and toluene (60 mL) at 90 °C to give the desired product as a pale yellow oil (6.178 g, 31.6 mmol, 89%): 1H NMR (CDCl3, 400 MHz) δ 4.40 (t, 2H. J = 8.2), 3.87 (t, 2H, J = 8.2), 2.29 (t, 2H, J = 7.0), 1.52 (qn, 2H, J =7.0), 1.40–1.20 (6H), 0.89 (t, 2H, J =7.0); 
13C NMR (CDCl3, 100 MHz) δ 156.8, 71.4, 70.1, 62.9, 47.2, 31.5, 28.9, 28.7, 22.7, 18.5, 14.2. HRMS (ESI) for C11H18NO2 [M+H]+ found 196.1343, calc. 196.1332. 
 
Representative Procedure B [Hsung coupling with acyclic carbamates]:[Error! Bookmark not defined.] A slurry of ynecarbamate (1.0 equiv), 1-bromoalkyne (1.2 equiv), CuSO4∙5H2O (0.2 equiv) 1,10-phenanthroline monohydrate (0.4 equiv), and K3PO4·H2O (2.0 equiv) in toluene (50–60 mL) was stirred at 70–90 °C for 48 h.  The mixture was cooled to room temperature, diluted with DCM and filtered through silica, washed with DCM, concentrated under reduced pressure and the crude residue was purified by flash chromatography with EtOAc/hexane or Et2O/hexane (1:20 to 1:10) to give the product. 
 
Methyl benzyl(hex-1-yn-1-yl)carbamate (1d)[Error! Bookmark not defined.] 
Representative Procedure B.  Prepared from methyl benzylcarbamate (6.955 g, 42.1 mmol, 1.0 equiv) and 1-bromohex-1-yne (8.136 g, 50.5 mmol, 1.2 equiv) using K3PO4·H2O (19.39 g. 84.2 mmol, 2.0 equiv), CuSO4·5H2O (2.103 g, 8.42 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (3.338 g, 16.8 mmol, 0.4 eq) and toluene (60 mL) at 80 °C to give the desired product as a pale yellow oil (7.277 g, 29.7 mmol, 70%): 1H NMR (CDCl3, 400 MHz) δ 7.39–7.27 (m, 5H), 4.59 (s, 2H), 3.80 (s, 3H), 2.25 (t, 2H, J = 7.3), 1.43 (qn, 2H, J = 7.3), 1.32 (sx, 2H, J = 7.3), 0.89 (t, 3H, J = 7.3); 13C NMR (CDCl3, 100 MHz) δ 156.4, 136.4, 128.6, 128.0, 73.9, 70.8, 54.1, 31.1, 21.9, 18.3, 13.7, two peaks not observed/overlapped. HRMS (ESI) for C15H20NO2 [M+H]+ found 246.1480, calc. 246.1489. 
 
Ethyl benzyl(hex-1-yn-1-yl)carbamate (1e) 







tert-Butyl benzyl(hex-1-yn-1-yl)carbamate (1f) 
Representative Procedure B.  Prepared from tert-butyl benzylcarbamate (4.972 g, 24.0 mmol, 1.0 equiv) and 1-bromohex-1-yne (4.64 g, 28.8 mmol, 1.2 equiv) using K3PO4·H2O (11.05 g. 48.0 mmol, 2.0 equiv), CuSO4·5H2O (1.20 g, 4.80 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (1.90 g, 9.60 mmol, 0.4 equiv) and toluene (80 mL) at 90 °C to give the desired product as a pale yellow oil (3.833 g, 13.3 mmol, 56%): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.20 (m, 5H), 4.50 (s, 2H), 2.20 (m, 2H), 1.50–1.35 (m, 2H), 1.30 (sx, 2H, J = 7.2), 0.83 (t, 3H, J = 7.2); 13C NMR (CDCl3, 100 MHz) δ 154.7, 137.0, 128.5, 128.2, 127.7, 82.1, 74.9, 69.8, 53.2, 31.1, 28.2, 21.9, 18.2, 13.7; HRMS (ESI) for C18H25NO2Na [M+Na]+ found 310.1776, calc. 310.1783. 
 
Benzyl benzyl(hex-1-yn-1-yl)carbamate (1g) 
Representative Procedure B.  Prepared form benzyl benzylcarbamate (4.3935 g, 18.2 mmol, 1.0 equiv) and 1-bromohex-1-yne (3.5187 g, 21.8 mmol, 1.2 equiv) using K3PO4·H2O (8.386 g, 36.4 mmol, 2.0 equiv), CuSO4·5H2O (0.9093 g, 3.64 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (1.4437 g, 7.28 mmol, 0.4 equiv) and toluene (40 mL) at 80 °C to give the desired product as a yellow oil 3.6119 g, 11.2 mmol, 62%): 1H NMR (CDCl3, 500 MHz) δ 7.50–7.30 (m, 10 H), 5.30 (s, 2H), 4.69 (s, 2H), 2.31 (m, 2H), 1.55–1.45 (qn, 2H, J = 7.2), 1.45–1.35 (sx, 2H, J = 7.2), 0.94 (t, 3H, J = 7.2); 13C NMR (CDCl3, 125 MHz) δ 155.7, 136.3, 135.9, 128.48, 128.47, 128.4, 128.2, 127.9, 127.7, 73.7, 70.6, 68.3, 53.8, 31.0, 21.8, 18.1, 13.6; HRMS (ESI) for C21H23NO2Na [M+Na]+ found 344.1620, calc. 344.1621.  
 
Methyl (4-chlorophenyl)(hex-1-yn-1-yl)carbamate (1h) 
Representative Procedure B.  Prepared from methyl (4-chlorophenyl)carbamate (5.466 g, 29.5 mmol, 1.0 equiv) and 1-bromohex-1-yne (5.69 g, 35.3 mmol, 1.2 equiv) using K3PO4·H2O (13.56 g, 58.9 mmol, 2.4 equiv), CuSO4·5H2O (1.471 g, 5.89 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (2.335 g, 11.8 mmol, 0.4 equiv) and toluene (60 mL) at 80 °C to give the desired product as an organge oil (4.585 g, 17.3 mmol, 59%): 1H NMR (CDCl3, 400 MHz) δ 7.39 (d, 2H, J = 8.6), 7.28 (d, 2H, J = 8.6), 3.81 (s, 3H), 2.29 (t, 2H, J = 6.9), 1.48 (qn, 2H, J = 6.9), 1.38 (sx, 2H, J = 6.9), 0.87 (t, 3H, J = 6.9); 13C NMR (CDCl3, 100 MHz) δ 155.1, 138.7, 132.1, 129.0, 125.6, 73.3, 70.5, 64.4, 31.0, 22.1, 18.2, 13.7; HRMS for C14H17ClNO2 [M+H]+ found 266.0932, calc. 266.0942. 
 
Methyl benzyl(oct-1-yn-1-yl)carbamate (1i)[Error! Bookmark not defined.] 





Methyl benzyl(4-((tert-butyldimethylsilyl)oxy)but-1-yn-1-yl)carbamate (1j) 
Representative Procedure B.  Prepared from methyl benzylcarbamate (2.197 g, 13.3 mmol, 1.0 equiv) and ((4-bromobut-3-yn-1-yl)oxy)(tert-butyl)dimethylsilane (4.2021 g, 16.0 mmol, 1.2 equiv) using K3PO4·H2O (7.352 g, 31.9 mmol, 2.4 equiv), CuSO4·5H2O (0.664 g, 2.66 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (1.0545 g, 5.32 mmol, 0.4 equiv) and toluene (50 mL) at 100 °C to give the desired product as a yellow oil (2.4914 g, 7.17 mmol, 54%) of product.  Yellow oil: 1H NMR (CDCl3, 400 MHz) δ 7.35–7.20 (m, 5H), 4.54 (s, 2H), 3.74 (s,3H), 3.60 (d, 2H, J = 7.1), 2.42 (d, 2H, J = 7.1), 0.84 (s, 9H), 0.00 (s, 6H); 13C NMR (CDCl3, 100 MHz) δ 156.2, 136.3, 128.5, 128.4, 128.0, 74.8, 67.6, 62.2, 54.0, 26.0, 22.9, 18.4, -5.24, one carbon not observed (PhCH2); HRMS (ESI) for C19H30NO3Si [M+H]+ found 348.1990, calc. 348.1989. 
 
Methyl benzyl(phenylethynyl)carbamate (1k)[8] 
Representative Procedure B.  Prepared from methyl benzylcarbamate (3.1557 g, 19.1 mmol, 1.0 equiv) and (bromoethynyl)benzene (4.1500 g, 22.9 mmol, 1.2 equiv) using K3PO4·H2O (8.798 g, 38.2 mmol, 2.0 equiv), CuSO4·5H2O (0.9540 g, 3.82 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (1.5147 g, 7.64 mmol, 0.4 equiv) and toluene (60 mL) at 100 °C to give the desired product as a yellow oil (3.660 g, 13.8 mmol, 72%): 1H NMR (CDCl3, 400 MHz) δ 7.50–7.20 (m, 10H), 4.76 (s, 2H), 3.89 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 155.7, 136.0, 131.3, 128.7, 128.3, 128.2, 127.7, 123.2, 83.1, 71.3, 54.3, 54.2, one carbon not observed (Ar). HRMS (ESI) for C17H16NO2 [M+H]+ found 266.1156, calc. 266.1176. 
 
3-(Prop-1-yn-1-yl)oxazolidin-2-one (1b):[9] 






Procedure D [Evano N-alkynylation using potassium alkynyltrifluoroborates]:[11] A slurry of potassium 1-hexynyltrifluoroborate (6.589 g, 35.0 mmol, 1 equiv), 2-benzoxazolinone (9.470 g, 70.1 mmol, 2 equiv), 1,2-dimethylimidazole (1.24 mL, 14.0, 0.2 equiv), CuCl2-2H2O (1.20 g, 7.01 mmol, 0.1 equiv) was stirred in DCM (20 mL) under dioxygen atmosphere (balloon) at 37 oC for 48 h.  The solvent was removed under reduced pressure and the residue was purified by flash chromatography (EtOAc/Hex 1:40) to give the product as a yellow oil (1.5354 g, 7.13 mmol. 20%): 1H NMR (CDCl3, 400 MHz) δ 7.2–7.0 (m, 4H, ArH), 2.40 (t, 2H, J = 7.0, CH2C≡C), 1.55 (qn, 2H, J = 7.0, CH2CH2C≡C), 1.43 (sx, 2H, J = 7.0, CH3CH2), 0.88 (t, 2H, J = 7.0, CH3); 13C NMR (CDCl3, 100 MHz) δ 153.0, 142.0, 130.0, 124.5, 124.1, 110.3, 110.1, 76.6, 64.9, 30.5, 21.9, 18.2, 13.6; HRMS for C13H14NO2 [M+H]+ found 216.1022, calc. 216.1019. 
 
3.2  Formation of Stereodefined Enolates 
  
 
3.2.1  One-Pot Procedure using Gilman Reagents 
Representative Procedure E 








(E)-Allyl (2-methyl-1-(2-oxooxazolidin-3-yl)hex-1-en-1-yl) carbonate (3a) 
Representative Procedure E.  Prepared from 3-(hex-1-yn-1-yl)oxazolidin-2-one (1.784 g, 10.7 mmol, 1 equiv) using MeLi (1.6 M in Et2O; 13.33 mL, 21.3 mmol, 2 equiv), CuBr·DMS (2.1934 g, 10.7 mmol, 1 equiv), TBHP (5.5 M in decane; 1.94 mL, 10.7 mmol, 1 equiv) and AllocCl (2.84 mL, 26.7 mmol, 2.5 equiv) to give the desired product as a pale yellow oil (2.101 g, 7.42 mmol, 70%): 1H NMR (CDCl3, 400 MHz) δ 5.93 (ddt, 1H, J = 16.6, 10.4, 5.7), 5.37 (d, 1H, J = 16.6), 5.28 (d, 1H, J = 10.4), 4.65 (d, 2H, J = 5.7), 4.37 (t, 2H, J = 7.9), 3.77 (t, 2H, J = 7.9), 2.05 (t, 2H, J = 7.0), 1.68 (s, 3H), 1.42 (qn, 2H, J = 7.0), 1.29 (sx, 2H, J = 7.0), 0.88 (t, 3H, J = 7.0); 13C NMR (CDCl3, 100 MHz) δ 154.6, 152.6, 131.0, 130.1, 125.8, 118.7, 68.4, 61.7, 44.3, 30.1, 28.3, 21.6, 15.2, 13.0. HRMS for C14H22NO5 [M+H]+ found 284.1490, calc. 284.1492. 
 
(Z)-Allyl (2-methyl-1-(2-oxooxazolidin-3-yl)hex-1-en-1-yl) carbonate (3b) 
Representative Procedure E.  Prepared from 3-(prop-1-yn-1-yl)oxazolidin-2-one (1.6736 g, 13.4 mmol, 1 equiv) using BuLi (1.6 M in hexanes; 16.7 mL, 26.7 mmol, 2 equiv), CuBr·DMS (2.750 g, 13.4 mmol, 1 equiv), TBHP (5.5 M in decane; 2.43 mL, 13.4 mmol, 1 equiv) and AllocCl (3.55 mL, 33.4 mmol, 2.5 equiv) to give the desired product as a yellow oil (1.964 g, 6.93 mmol, 52%): 1H NMR (CDCl3, 400 MHz) δ 5.95 (ddt, 1H, J = 17.2, 10.4, 5.8), 5.40 (d, 1H, J = 17.2), 5.30 (dd, 1H, J = 10.4, 1.3), 4.68 (d, 2H, J = 5.8), 4.40 (t, 2H, J = 7.8), 3.82 (t, 2H, J = 7.8), 2.08 (t, 2H, J = 7.2), 1.71 (s, 3H), 1.42 (qn, 2H, J = 7.2), 1.32 (sx, 2H, J = 7.2), 0.90 (t, 3H, J = 7.2); 13C NMR (CDCl3, 100 MHz) δ 154.6, 152.6, 131.0, 130.1, 125.8, 118.7, 68.4, 61.7, 44.3, 30.1, 28.3, 21.6, 15.2, 13.0; HRMS for C14H22NO5 [M+H]+ found 284.1495, calc. 284.1492. 
 
(E)-Allyl (2-methyl-1-(2-oxobenzo[d]oxazol-3(2H)-yl)hex-1-en-1-yl) carbonate (3c) 
Representative Procedure E.  Prepared from 3-(hex-1-yn-1-yl)benzo[d]oxazol-2(3H)-one (130 g, 0.604 mmol, 1 equiv) using MeLi (1.6 M in Et2O; 906 µL, 1.45 mmol, 2.4 equiv), CuBr·DMS (150 mg, 0.730 mmol, 1.2 equiv), TBHP (5.5 M in decane; 132 µL, 0.730 mmol, 1.2 equiv) and AllocCl (257 µL, 2.42 mmol, 4 equiv) to give the desired product as a yellow oil (97.6 mg, 0.295 mmol, 49%): 1H NMR (CDCl3, 500 MHz) δ 7.22–7.12 (m, 4H), 5.89 (ddt, 1H, J = 17.3, 10.5, 5.8), 5.34 (dqt, 1H, J = 17.3, 1.3), 5.26 (dqt, 1H, J = 10.5, 1.23), 4.62 (dqt, 2H, J = 5.8, 1.3), 2.00 (td, 2H, J = 7.6, 3.6), 1.88 (s, 3H), 1.50–1.30 (m, 2H), 1.21 (sx, 2H, J = 7.5), 0.79 (t, 3H, J = 7.5); 




3.2.2  Two-Step Procedure Using Grignard Reagents 
3.2.2.1  Carbometallation–Iodination Products 
Representative Procedure F 
Carbometallation–Iodination: A solution of ynecarbamate (1 equiv) in Et2O (5–10 mL) was added to a suspension of CuI (1 equiv) and RMgBr (in Et2O; 2 equiv) in Et2O (15–25 mL) at – 30 °C and the mixture was left to stir gradually warming up to –10 °C.  After 1 h, a solution of iodine (2 equiv) in THF (10–20 mL) was added dropwise at –10 °C and the mixture left for 15 min.  It was then quenched with sat. aq. Na2S2O3 solution and extracted with Et2O (2×), the combined organic layers were dried over MgSO4, filtered, concentrated and purified by flash chromatography Et2O/hexane or Et2O/pentane (1:20 to 1:10) to give the desired product. 
 
(E)-Methyl benzyl(1-iodo-2-methylhex-1-en-1-yl)carbamate (4d) 
Representative Procedure F.  Prepared from methyl benzyl(hex-1-yn-1-yl)carbamate (200 mg, 0.815 mmol, 1 equiv) using CuI (155 mg, 0.815 mmol, 1 equiv), MeMgBr (3 M in Et2O; 0.69 mL, 1.63 mmol, 2 equiv) and iodine (424 mg, 1.63 mmol, 2 equiv) to give the desired product as a pale yellow oil (316 mg, 0.815 mmol, quant): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.25 (m, 5H), 4.98 (d, 1H, J = 14.2), 4.05 (d, 1H, J = 14.2), 3.81 (s, 3H), 1.77 (s, 3H), 1.70 (td, 1H, J = 13.2, 5.2), 1.55 (m, 1H), 1.15–1.05 (m, 1H), 1.05–0.90 (m, 2H), 0.73 (t, 3H, J = 7.2), 0.65–0.50 (m, 1H); 13C NMR (CDCl3, 75 MHz) δ 155.5, 146.2, 135.8, 129.9, 128.3, 127.8, 95.3, 53.6, 52.2, 33.5, 29.1, 25.9, 22.7, 13.8; HRMS (APCI) for C20H31INO2 [M+H]+ found 338.0770, calc. 338.0768. 
 
(E)-Ethyl benzyl(1-iodo-2-methylhex-1-en-1-yl)carbamate (4e) 
Representative Procedure F.  Prepared from ethyl benzyl(hex-1-yn-1-yl)carbamate (1.5237 g, 5.88 mmol, 1 equiv) using CuI (1.119 g, 5.88 mmol, 1 equiv), MeMgBr (3 M in Et2O; 3.92 mL, 11.8 mmol, 2 equiv) and iodine (2.982 mg, 11.8 mmol, 2 equiv) to give the desired product as a yellow oil (1.728 g, 4.31 mmol, 73%): 1H NMR (CDCl3, 300 MHz) δ 7.31–7.13 (m, 5H), 4.87 (d, 1H, J = 14.2), 4.24–4.07 (m, 2H), 3.91 (d, 1H, J = 14.2), 1.69 (s, 3H), 1.63–1.53 (m, 1H), 1.57–1.37 (m, 1H), 1.20 (m, 3H, J = 7.0), 0.62 (t, 3H, J = 7.2), 0.50–0.33 (m, 1H); 13C NMR (CDCl3, 75 MHz) δ 155.0, 145.8, 135.9, 129.9, 128.3, 127.7, 95.7, 62.4, 52.0, 33.5, 29.2, 25.8, 22.7, 14.7, 13.8; HRMS for C17H25INO2 [M+H]+ found 402.0975, calc. 402.0924. 
 
(E)-tert-Butyl benzyl(1-iodo-2-methylhex-1-en-1-yl)carbamate (4f) 





(E)-Benzyl benzyl(1-iodo-2-methylhex-1-en-1-yl)carbamate (4g) 
Representative Procedure F.  Prepared from benzyl benzyl(hex-1-yn-1-yl)carbamate (0.618 g, 1.92 mmol, 1 equiv) using CuI (0.366 g, 1.92 mmol, 1 equiv), MeMgBr (3 M in Et2O; 1.28 mL, 3.85 mmol, 2 equiv) and iodine (0.976 g, 3.85 mmol, 2 equiv) to give the desired product as a pale yellow oil (0.891 g, 1.92 mmol, quant): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.10 (m, 10H), 5.20–5.05 (m, 2H), 4.90 (d, 1H, J = 13.9), 3.95 (d, 1H, J =13.9), 1.64 (s, 3H), 1.60-1.45 (m, 2H), 1.00–0.65 (m, 3H), 0.60–0.50 (m, 3H), 0.40–0.25 (m, 1H); 13C NMR (CDCl3, 100 MHz) δ 154.9, 146.3, 136.3, 135.7, 129.9, 128.4, 128.3, 128.0, 127.8, 95.0, 68.0, 52.2, 33.6, 29.1, 25.8, 22.7, 13.7, one carbon not observed (Ar); HRMS (APCI) for C22H27INO2 [M+H]+ found 464.1073, calc. 464.1081. 
 
(E)-Methyl (4-chlorophenyl)(2-methyl-1-iodohex-1-en-1-yl)carbamate (4h) 
Representative Procedure F.  Prepared from benzyl methyl (4-chlorophenyl)(hex-1-yn-1-yl)carbamate (0.710 g, 2.67 mmol, 1 equiv) using CuI (0.509 g, 2.67 mmol, 1 equiv), MeMgBr (3 M in Et2O; 1.78 mL, 5.34 mmol, 2 equiv) and iodine (1.356 g, 5.34 mmol, 2 equiv) to give the desired product as a yellow oil (0.949 g, 2.33 mmol, 87%): 1H NMR (CDCl3, 500 MHz) δ 7.40–7.30 (m, 4H), 3.83 (s, 3H), 2.35–2.25 (m, 1H), 2.18 (td, 1H, J = 10.3, 4.4), 1.94 (s, 3H), 1.45–1.35 (m, 1H), 1.35–1.15 (m, 3H), 0.88 (t, 3H, J = 7.2); 13C NMR (CDCl3, 125 MHz) δ 154.0, 146.6, 139.1, 131.5, 128.9, 125.5, 92.9, 53.7, 33.4, 29.2, 26.1, 22.8, 13.9; HRMS (ESI) for C15H20ClNIO2 [M+H]+ found 408.0221, calc. 408.0222. 
 
(E)-Methyl benzyl(1-iodo-2-methyloct-1-en-1-yl)carbamate (4i) 





(E)-Methyl benzyl(4-((tert-butyldimethylsilyl)oxy)-1-iodo-2-methylbut-1-en-1-yl)carbamate (4j) 
Representative Procedure F.  Prepared from methyl benzyl(4-((tert-butyldimethylsilyl)oxy)but-1-yn-1-yl)carbamate (0.542 g, 1.56 mmol, 1 equiv) using CuI (0.297 g, 1.56 mmol, 1 equiv), MeMgBr (3 M in Et2O; 1.04 mL, 3.12 mmol, 2 equiv) and iodine (0.792 g, 3.12 mmol, 2 equiv) to give the desired product as a pale yellow oil (0.703 g, 1.44 mmol, 92%): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.20 (m, 5H), 4.95 (d, 1H, J =13.9), 4.12 (d, 1H, J = 13.9), 3.81 (s, 3H), 3.30–3.10 (m, 2H), 2.10–2.00 (m, 2H), 1.92–1.78 (m, 4H), 0.88 (s, 9H), 0.0074 (s, 3H), –0.0001 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 155.4, 143.4, 135.4, 130.0, 128.3, 127.9, 97.1, 60.8, 53.6, 52.6, 36.9, 26.6, 25.9, 18.2, –5.35l; HRMS (APCI) for C20H33INO3Si [M+H]+ found 490.1282, calc. 490.1269. 
 
(E)-Methyl benzyl(1-iodo-2-phenylprop-1-en-1-yl)carbamate (4k) 
Representative Procedure F.  Prepared from methyl benzyl(phenylethynyl)carbamate (0.500 g, 1.88 mmol, 1 equiv) using CuI (0.359 g, 1.88 mmol, 1 equiv), MeMgBr (3 M in Et2O; 1.26 mL, 3.77 mmol, 2 equiv) and iodine (0.957 g, 3.77 mmol, 2 equiv) to give the desired product as a pale yellow oil (0.551 g, 1.35 mmol, 72%): 1H NMR (CDCl3, 400 MHz) δ 7.20–6.95 (m, 6H), 6.95–6.80 (m, 2H), 6.70–6.50 (m, 2H), 4.31 (d, 1H, J = 13.9), 4.04 (d, 1H, J =13.9), 3.71 (s, 3H), 2.03 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 155.8, 144.8, 139.4, 134.8, 129.6, 128.1, 127.4, 127.1, 126.6, 98.1, 53.6, 53.1, 29.6, one carbon not observed (overlapped in Ar); HRMS (APCI) for C18H19INO2 [M+H]+ found 408.0447, calc. 408.0455. 
 
(E)-Methyl benzyl(2-ethyl-1-iodohex-1-en-1-yl)carbamate (4l) 





(E)-Methyl benzyl(2-ethyl-1-iodooct-1-en-1-yl)carbamate (4m) 
Representative Procedure F.  Prepared from methyl benzyl(oct-1-yn-1-yl)carbamate (0.464 g, 1.69 mmol, 1 equiv) using CuI (0.323 g, 1.69 mmol, 1 equiv), EtMgBr (1.9 M in Et2O; 1.78 mL, 3.39 mmol, 2 equiv) and iodine (0.860 g, 3.39 mmol, 2 equiv) to give the desired product as a pale yellow oil (0.621 g, 1.45 mmol, 85%): 1H NMR (CDCl3, 500 MHz) δ 7.40–7.25 (m, 5H), 4.98 (d, 1H, J = 13.5), 4.02 (d, 1H, J = 13.5), 3.79 (s, 3H), 2.25–2.15 (m, 1H), 2.15–2.05 (m, 1H), 1.68 (td, 1H, J =13.1, 4.9), 1.55–1.40 (m, 1H), 1.30–1.25 (m, 2H), 1.15–0.90 (m, 5H), 0.90 (t, 3H, J = 7.4), 0.87 (t, 3H, J = 7.3), 0.70–0.60 (m, 1H); 13C NMR (CDCl3, 125 MHz) δ 150.9, 135.6, 130.2, 128.3, 127.9, 53.6, 52.1, 31.7, 31.6, 31.3, 29.5, 27.1, 22.6, 14.2, 11.7, two carbons not observed (C=C); HRMS (APCI) for C19H29INO2 [M+H]+ found 430.1237, calc. 430.1240. 
 
Methyl (Z)-benzyl(1-iodo-2-(3-phenylpropyl)oct-1-en-1-yl)carbamate (4n) 
Representative Procedure F.  Prepared from methyl benzyl(oct-1-yn-1-yl)carbamate (1.029 g, 3.76 mmol, 1 equiv) using CuI (0.717 g, 3.76 mmol, 1 equiv), Ph(CH2)3MgBr (2.3 M in Et2O; 3.27 mL, 7.53 mmol, 2 equiv) and iodine (1.911 g, 7.53 mmol, 2 equiv) to give the desired product as a yellow oil (1.801 g, 3.47 mmol, 92%): 1H NMR (CDCl3, 500 MHz) δ 7.41–7.37 (m, 2H), 7.37–7.29 (m, 5H), 7.26–7.20 (m, 3H), 5.05 (br d, 1H, J = 13.5), 4.05 (br d, 1H, J = 13.5), 3.82 (s, 3H), 2.64 (td, J = 7.6, 1.6), 2.27–2.10 (m, 2H), 1.77–1.60 (m, 2H), 1.58–1.48 (br s, 1H), 1.24 (qn, 2H, J = 7.4), 1.13–0.92 (m, 6H), 0.90 (m, 3H, J = 7.4), 0.63–0.52 (m, 1H); 13C NMR (CDCl3, 125 MHz) δ 155.6, 149.4, 142.1, 135.6, 130.1, 128.5, 128.37, 128.35, 127.9, 125.9, 95.8, 53.6, 52.1, 37.9, 35.7, 31.6, 31.5, 29.4, 28.9, 27.1, 22.6, 14.2; HRMS (APCI) for C26H35INO2 [M+H]+ found 520.1711, calc. 520.1707. 
 
(E)-3-(2-Ethyl-1-iodohex-1-en-1-yl)oxazolidin-2-one (4o) 
Representative Procedure F.  Prepared from 3-(hex-1-yn-1-yl)oxazolidin-2-one (0.920 g, 5.50 mmol, 1 equiv) using CuI (1.049 g, 5.50 mmol, 1 equiv), EtMgBr (2.7 M in Et2O; 4.08 mL, 11.0 mmol, 2 equiv) and iodine (2.793 g, 11.0 mmol, 2 equiv) to give the desired product as a yellow oil (1.630 g, 5.04 mmol, 92%): 1H NMR (CDCl3, 300 MHz) δ 4.45–4.25 (m, 2H), 3.64 (q, 1H, J = 9.5), 3.40–3.25 (m, 1H), 2.30–2.10 (m, 4H), 1.50–1.15 (m, 4H), 1.00 (t, 3H, J = 7.3), 0.85 (t, 3H, J = 7.3); 13C NMR (CDCl3, 75 MHz) δ 155.8, 153.5, 90.1, 62.0, 46.6, 32.0, 31.3, 30.1, 22.7, 13.8, 11.7; HRMS (ESI) for C11H19INO2 [M+H]+ found 324.0450, calc. 324.0455. 
 
(E)-3-(2-Ethyl-1-iodooct-1-en-1-yl)oxazolidin-2-one (4p) 
Representative Procedure F.  Prepared from 3-(oct-1-yn-1-yl)oxazolidin-2-one (0.9911 g, 5.08 mmol, 1 equiv) using CuI (0.9667 g, 5.08 mmol, 1 equiv), EtMgBr (2.7 M in Et2O; 3.76 mL, 10.15 mmol, 2 equiv) and iodine (2.577 g, 10.15 mmol, 2 equiv) to give the desired product as a yellow oil (1.5244 g, 4.34 mmol, 86%): 1H NMR (CDCl3, 300 MHz) δ 4.42–4.24 (m, 2H), 3.63 (q, 1H, J = 9.5), 3.35–3.23 (m, 1H), 2.22–2.06 (m, 4H), 1.47–1.24 (m, 2H), 1.24–1.12 (m, 8H), 0.97 (t, 3H, J = 7.3), 0.80 (t, 3H, J = 7.3); 13C NMR (CDCl3, 75 MHz) δ 155.7, 153.3, 90.1, 62.0, 46.5, 31.9, 31.5, 31.4, 29.2, 27.8, 22.4, 14.0, 11.6; HRMS (ESI) for C13H23INO2 [M+H]+ found 352.0740, calc. 352.0768. 
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3.2.2.2  Regioretentive Formation of Alloc-Trapped Products 
Representative Procedure G 
Representative Procedure for Regioretentive Formation of Alloc-Trapped Products: A solution of MeLi in Et2O (2.1 equiv) was added dropwise to a solution of tBuOOH (5.5 M in decane; 1.8 equiv) in THF (15 mL) at –80 °C.  After the addition of base was complete, the mixture was stirred for additional 15–30 min prior to be used as an in situ prepared oxidant.  
A solution of tBuLi in hexane (2.1 equiv) was added dropwise to a solution of vinyl iodide 5 (1 equiv) in Et2O at –80 °C.  After 15 min, a solution of freshly prepared tBuOOLi (see above; ca. 1.5 equiv) was added via syringe at –80 °C and the mixture was left to stir warming up to –40 °C.  After 1 h, AllocCl (4.5 equiv) was added and the reaction mixture was allowed to warm to room temperature.  It was quenched with 1 M HCl solution, extracted with Et2O (2×), the combined organic layers were dried over MgSO4, filtered, concentrated and purified by flash chromatography (Et2O/hexane or EtOAc/hexane) to give the desired product. 
 
(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3d) 
Representative Procedure G.  Prepared from vinyl iodide 4d (1.611 g, 4.16 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 4.89 mL, 8.32 mmol, 2.0 equiv), TBHP (5.5 M in decane; 1.51 mL, 8.32 mmol, 2.0 equiv) using MeLi (1.6 M in Et2O; 5.98 mL, 9.57 mmol, 2.3 equiv) and AllocCl (1.77 µL, 16.64 mmol, 4.0 equiv) to give the desired product as a yellow oil (1.082 g, 2.99 mmol, 72%): 1H NMR (CDCl3, 400 MHz) δ 7.4–7.10 (m, 5H), 5.83 (ddt, 1H, J = 17.2, 10.4, 5.5), 5.30 (d, 1H, J = 17.2), 5.22 (d, 1H, J = 10.4), 4.66 (d, 1H, J = 14.6), 4.51 (d, 2H, J = 5.5), 4.41 (d, 1H, J = 14.6), 3.71 (s, 3H), 1.75–1.60 (m, 2H), 1.55 (s, 3H), 1.10–0.90 (m, 2H), 0.90–0.75 (m, 2H), 0.72 (t, 3H, J = 7.2); 13C NMR (CDCl3, 100 MHz) δ 156.3, 152.7, 137.5, 134.8, 131.2, 128.8, 128.3, 127.4, 126.1, 119.2, 68.9, 53.3, 51.2, 32.0, 28.9, 22.7, 14.9, 13.9; HRMS (ESI) for C20H28NO5 [M+H]+ found 362.1960, calc. 362.1962. 
 
(E)-Ethyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3e) 





(E)-tert-Butyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3f)  
Representative Procedure G.  Prepared from vinyl iodide 4f (0.300 g, 0.70 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 822 µL, 1.40 mmol, 2.0 equiv), TBHP (5.5 M in decane; 254 µL, 1.40 mmol, 2.0 equiv) using MeLi (1.6 M in Et2O; 1.00 mL, 1.61 mmol, 2.3 equiv) and AllocCl (334 µL, 3.14 mmol, 4.5 equiv) to give the desired product as a yellow oil (0.230 g, 0.57 mmol, 82%): 1H NMR (CDCl3, 400 MHz) δ 7.45–7.10 (m, 5H), 5.81 (ddt, 1H, J = 17.2, 10.4, 5.6), 5.27 (d, 1H, J = 17.2), 5.18 (d, 1H, J = 10.4), 4.67 (br s, 1H), 4.48 (d, 2H, J = 5.6), 4.33 (d, 1H, J = 14.5), 1.7–1.55 (m, 2H), 1.54 (s, 3H), 1.38 (s, 9H), 1.25–0.80 (m, 4H), 0.70 (t, 3H, J = 7.0); 13C NMR (CDCl3, 125 MHz) δ NMR 154.7, 152.9, 138.1, 135.5, 131.4, 128.7, 128.3, 127.2, 119.2, 80.8, 77.4, 68.9, 50.5, 32.3, 29.1, 28.3, 22.8, 14.0; HRMS (ESI) for C23H34NO5 [M+H]+ found 404.2433, calc. 404.2431. 
 
(E)-Benzyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3g) 
Representative Procedure G.  Prepared from vinyl iodide 4g (0.517 g, 1.12 mmol, 1 equiv) using tBuLi (1.6 M in hexane; 1.40 mL, 2.23 mmol, 2.0 equiv), TBHP (5.5 M in decane; 365 µL, 2.01 mmol, 1.8 equiv) using MeLi (1.24 M in Et2O; 1.89 mL, 2.34 mmol, 2.1 equiv) and AllocCl (534 µL, 5.02 mmol, 4.5 equiv) to give the desired product as a yellow oil (0.383 g, 0.875, 78%): 1H NMR (CDCl3, 500 MHz) δ 7.45–7.10 (m, 10H), 5.79 (ddt, 1H, J = 17.1, 10.4, 5.7), 5.26 (dd, 1H, J = 17.1, 1.3), 5.19 (d, 1H, J = 10.4), 5.20–5.10 (m, 2H), 4.64 (br d, 1H, J = 14.6), 4.47 (d, 1H, J =5.7), 4.40 (br d, 1H, J = 14.6), 1.60–1.45 (m, 5H), 1.10–0.75 (m, 4H), 0.75–0.55 (m, 3H); 13C NMR (CDCl3, 125 MHz) δ 155.7, 152.8, 137.5, 136.4, 134.7, 131.3, 128.8, 128.4, 128.3, 128.0, 127.9, 127.4, 126.2, 119.2, 69.0, 67.9, 51.3, 32.2, 28.9, 22.7, 15.0, 13.9; HRMS (ESI) for C26H32NO5 [M+H]+ found 438.2269, calc. 438.2275. 
 
(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(4-chlorophenyl)carbamate (3h) 






(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-methyloct-1-en-1-yl)(benzyl)carbamate (3i) 
Representative Procedure G.  Prepared from vinyl iodide 4i (0.509 g, 1.23 mmol, 1 equiv) using tBuLi (1.6 M in hexane; 1.53 mL, 2.45 mmol, 2.0 equiv), TBHP (5.5 M in decane; 401 µL, 2.21 mmol, 1.8 equiv) using MeLi (1.24 M in Et2O; 2.08 mL, 2.57 mmol, 2.1 equiv) and AllocCl (586 µL, 5.52 mmol, 4.5 equiv) to give the desired product as a yellow oil (0.387 g, 0.99 mmol, 81%): 1H NMR (CDCl3, 400 MHz) δ 7.35–7.10 (m, 5H), 5.79 (ddt, 1H, J = 17.1, 10.4, 5.7), 5.26 (dd, 1H, J = 17.1, 1.2), 5.18 (d, 1H, J = 10.4), 4.63 (br d, 2H, J = 14.5), 4.47 (d, 1H, J = 5.7), 4.37 (br d, J = 14.5), 3.67 (s, 3H), 1.70–1.55 (m, 2H), 1.51 (s, 3H), 1.25–1.10 (m, 4H), 1.04 (qn, 2H, J = 7.2), 1.00–0.90 (m, 2H), 0.85 (t, 3H, J = 7.3), 0.78 (t, 3H, J = 7.2); 13C NMR (CDCl3, 100 MHz) δ 156.3, 152.7, 137.5, 134.8, 131.2, 128.8, 128.3, 127.4, 126.0, 119.15, 68.9, 53.3, 51.2, 32.2, 31.7, 29.3, 26.7, 22.6, 14.9, 14.1; HRMS (ESI) for C22H32NO5 [M+H]+ found 390.2288, calc. 390.2275. 
 
Methyl (E)-benzyl(2,2,3,3,7-pentamethyl-10-oxo-4,9,11-trioxa-3-silatetradeca-7,13-dien-8-yl)carbamate (3j) 
Representative Procedure G.  Prepared from vinyl iodide 4j (0.802 g, 1.64 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 1.93 mL, 3.28 mmol, 2.0 equiv), TBHP (5.5 M in decane; 596 µL, 3.28 mmol, 2.0 equiv) using MeLi (1.24 M in Et2O; 3.04 mL, 3.77 mmol, 2.3 equiv) and AllocCl (784 µL, 7.37 mmol, 4.5 equiv) to give the desired product as a pale yellow oil (677g, 1.46 mmol, 89%): 1H NMR (CDCl3, 500 MHz) δ 7.38–7.21 (m, 5H), 5.85 (ddt, 1H, J = 17.2, 10.4, 5.7), 5.33 (dqt, 1H, J = 17.2, 1.2), 5.26 (dd, 1H, J = 10.5, 1.2), 4.67–4-52 (br m, 2H) 4.52 (d, 2H, J = 5.7), 3.76 (s, 3H) 2.00 (t, 2H, J = 7.2), 3.52–3.30 (br m, 2H), 2.07–1.91 (br m, 2H), 1.63 (s, 3H), 0.86 (s, 9H), –0.01 (s, 6H); 13C NMR (CDCl3, 125 MHz) δ 156.3, 152.5, 137.5, 136.3, 131.3, 128.8, 128.4, 127.5, 123.5, 119.4, 69.1, 60.9, 53.5, 51.7, 35.7, 26.0, 18.4, 15.7, –5.27; HRMS (ACPI) for C24H38NO6Si [M+H]+ found 464.2452, calc. 464.2463. 
 
Methyl (E)-(1-(((allyloxy)carbonyl)oxy)-2-phenylprop-1-en-1-yl)(benzyl)carbamate (3k) 





Methyl (E)-(1-(((allyloxy)carbonyl)oxy)-2-ethylhex-1-en-1-yl)(benzyl)carbamate (3l) 
Representative Procedure G.  Prepared from vinyl iodide 4l (0.395 g, 0.984 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 1.16 mL, 1.97 mmol, 2.0 equiv), TBHP (5.5 M in decane; 358 µL, 1.97 mmol, 2.0 equiv) using MeLi (1.25 M in Et2O; 1.81 mL, 2.26 mmol, 2.1 equiv) and AllocCl (470 µL, 4.43 mmol, 4.5 equiv) to give the desired product as a yellow oil (0.317 g, 0.844 mmol, 86%): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.10 (m, 5H), 5.81 (ddt, 1H, J = 17.2, 10.4, 5.7), 5.28 (d, 1H, J = 17.2, 1.2), 5.20 (d, 1H, J = 10.4, 1.2), 4.67 (br d, 2H, J = 14.2), 4.48 (dt, 1H, J = 5.7, 1.2), 4.37 (br d, J = 14.2), 3.68 (s, 3H), 1.93 (q, 2H, J = 7.3), 1.70–1.40 (m, 2H), 1.25–0.94 (m, 4H), 0.86 (t, 3H, J = 7.3), 0.70 (t, 3H, J = 7.3); 13C NMR (CDCl3, 100 MHz) δ 153.1, 137.5, 134.5, 131.4, 131.2, 129.0, 128.4, 127.5, 119.3, 69.1, 53.4, 51.3, 29.3, 28.9, 23.0, 21.7, 14.0, 11.8, one of the C=O peaks not observed; HRMS (APCI) for C21H30NO5 [M+H]+ found 376.2104, calc. 376.2118. 
 
Methyl (E)-(1-(((allyloxy)carbonyl)oxy)-2-ethyloct-1-en-1-yl)(benzyl)carbamate (3m) 
Representative Procedure G.  Prepared from vinyl iodide 4m (0.352 g, 0.820 mmol, 1 equiv) using tBuLi (1.6 M in hexane; 1.02 mL, 1.64 mmol, 2.0 equiv), TBHP (5.5 M in decane; 268 µL, 1.48 mmol, 1.8 equiv) using MeLi (1.24 M in Et2O; 1.39 mL, 1.72 mmol, 2.1 equiv) and AllocCl (392 µL, 3.69 mmol, 4.5 equiv) to give the desired product as a yellow oil (0.299 g, 0.75 mmol, 90%): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.10 (m, 5H), 5.80 (ddt, 1H, J = 17.2, 10.4, 5.6), 5.26 (d, 1H, J = 17.2), 5.19 (d, 1H, J = 10.4), 4.66 (br d, 2H, J = 14.5), 4.47 (d, 1H, J = 5.6), 4.36 (br d, J = 14.5), 3.67 (s, 3H), 1.92 (q, 2H, J = 7.2), 1.70–1.40 (m, 2H), 1.25–1.10 (m, 4H), 1.04 (qn, 2H, J = 7.2), 1.00–0.90 (m, 2H), 0.85 (t, 3H, J = 7.3), 0.78 (t, 3H, J = 7.2); 13C NMR (CDCl3, 100 MHz) δ 156.4, 153.0, 137.4, 134.4, 131.3, 131.1, 128.9, 128.3, 127.5, 119.2, 68.9, 53.3, 51.1, 31.7, 29.50, 29.45, 26.7, 22.6, 21.6, 14.1, 11.7; HRMS (ESI) for C23H34NO5 [M+H]+ found 404.2435, calc. 404.2435. 
 
Methyl (Z)-(1-(((allyloxy)carbonyl)oxy)-2-(3-phenylpropyl)oct-1-en-1-yl)(benzyl)carbamate (3n) 
Representative Procedure G.  Prepared from vinyl iodide 4o (0.868 g, 1.67 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 1.97 mL, 3.34 mmol, 2.0 equiv), TBHP (5.5 M in decane; 607 µL, 3.34 mmol, 2.0 equiv) using MeLi (1.2 M in Et2O; 3.20 mL, 3.84 mmol, 2.3 equiv) and AllocCl (888 µL, 8.35 mmol, 5.0 equiv) to give the desired product as a yellow oil (0.681 g, 1.38 mmol, 82%): 1H NMR (CDCl3, 500 MHz) δ 7.39–7.31 (m, 2H), 7.31–7.21 (m, 5H), 7.21–7.12 (m, 3H), 5.87 (ddt, 1H, J = 17.2, 10.4, 5.6), 5.34 (dqt, 1H, J = 17.2, 1.2), 5.28 (dd, 1H, J = 10.4, 1.2), 4.76 (br d, 2H, J = 14.6), 4.52 (dd, 1H, J = 5.6, 1.2), 4.41 (br d, J = 14.6), 3.75 (s, 3H), 2.62–2.46 (m, 2H), 2.07–1.94 (m, 2H), 1.75–1.57 (m, 4H), 1.24–1.15 (m, 4H), 1.13–1.05 (m, 2H), 1.03–0.97 (m, 2H), 0.86 (t, 3H, J = 7.2); 





(E)-Allyl (2-ethyl-1-(2-oxooxazolidin-3-yl)hex-1-en-1-yl) carbonate (3o) 
Representative Procedure G.  Prepared from vinyl iodide 4p (1.625 g, 5.03 mmol, 1 equiv) using tBuLi (1.56 M in hexane; 6.45 mL, 10.06 mmol, 2.0 equiv), TBHP (5.5 M in decane; 1.83 mL, 10.06 mmol, 2.0 equiv) using MeLi (1.6 M in Et2O; 7.23 mL, 11.57 mmol, 2.3 equiv) and AllocCl (2.41 mL, 22.6 mmol, 4.5 equiv) to give the desired product as a yellow oil (1.188 g, 4.11 mmol, 79%): 1H NMR (CDCl3, 400 MHz) δ 5.87 (ddt, 1H, J = 17.2, 10.8, 5.7), 5.31 (d, 1H, J = 17.2, 1.3), 5.22 (d, 1H, J = 10.8, 1.3), 4.59 (dt, 2H, J = 5.7, 1.2), 4.31 (t, 2H, J = 7.7), 3.74 (d, 2H, J = 7.7), 2.10–1.95 (m, 4H), 1.36 (qn, 2H, J = 6.9), 1.25 (sx, 2H, J = 6.9), 1.01 (t, 3H, J = 7.6), 0.87 (t, 3H, J = 6.9); 13C NMR (CDCl3, 100 MHz) δ 155.8, 153.3, 132.1, 131.7, 130.9, 119.2, 69.0, 62.5, 45.6, 29.3, 29.1, 22.6, 21.9, 13.8, 11.9; HRMS for C15H24NO5 [M+H]+ found 298.1623, calc. 298.1649. 
 
(E)-Allyl (2-ethyl-1-(2-oxooxazolidin-3-yl)oct-1-en-1-yl) carbonate (3p) 




3.3 Decarboxylative Allylic Alkylation 




Methyl 2-bromo-5-(trifluoromethyl)benzoate (S2) 





Methyl 2-(bis(4-(trifluoromethyl)phenyl)phosphoryl)-5-(trifluoromethyl)benzoate (S3) 
Procedure adapted from Stankevič and Włodarcyk.[14]  To an oven dried Schlenk tube equipped with a magnetic 
stir bar was added CuI (0.145 g, 0.761 mmol).  The tube was purged with nitrogen and (S)--phenylethylamine (0.100 mL, 0.760 mmol) was added with a micro-syringe followed by S2 (1.09 g, 3.8 mmol) dissolved in toluene (19.0 mL) with a syringe.  The reaction mixture was stirred under nitrogen for 5 minutes at room temperature.  Bis(4-(trifluoromethyl)phenyl)phosphine oxide[Error! Bookmark not defined.] (1.30 g, 3.84 mmol) was added to the reaction mixture in one portion and stirring continued for five minutes.  Potassium carbonate (1.05 g, 7.60 mmol) was added to the reaction mixture and the tube was sealed with a Teflon cap and electrical tape and heated to 110 °C behind a blast shield for 24 hours.  The mixture was cooled to room temperature and the mixture was filtered through a pad of celite, eluting with dichloromethane.  This mixture was concentrated in vacuo and purified by flash chromatography (30:70 to 35/65, EtOAc/hexanes) to provide the product as an amorphous white solid (1.61 g, 78% yield); 1H NMR (500 MHz, CDCl3) δ 8.27 – 8.22 (m, 1H), 7.95 – 7.87 (m, 2H), 7.84 – 7.73 (m, 8H), 3.59 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 165.7 (d, J = 2.5 Hz), 136.7 – 136.6 (m), 136.2 (d, J = 6.3 Hz), 135.8 (d, J = 10.4 Hz), 135.8 (m), 134.9 (qd, J = 34.2, 2.4 Hz), 134.2 (qd, J = 32.9, 3.0 Hz), 132.3 (d, J = 10.4 Hz), 128.5 (dq, J = 11.9, 3.6 Hz), 127.9 (dq, J = 7.2, 3.5 Hz), 125.7 (dq, J = 12.8, 3.7 Hz), 123.5 (q, J = 272.6 Hz), 123.0 (q, J = 273.1 Hz), 53.1; 19F NMR (282 MHz, CDCl3) δ -63.2, -63.4; 31P NMR (121 MHz, CDCl3) δ 28.7; IR (Neat Film, NaCl) 1737, 1440, 1324, 1269, 1131, 715 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C23H15F9O3P [M+H]+: 541.0610, found 541.0616. 
 
Methyl 2-(bis(4-(trifluoromethyl)phenyl)phosphanyl)-5-(trifluoromethyl)benzoate (S4) 
To an oven-dried Schlenk flask equipped with a magnetic stir bar was added S3 (0.650 g, 1.20 mmol) in toluene (17.5 mL).  The mixture was stirred under flow of nitrogen at room temperature.  Triethylamine (0.730 mL, 5.22 mmol) was added to the reaction mixture followed by trichlorosilane (0.510 mL, 5.04 mmol) with a syringe.  At this stage, the reaction mixture was heated to 110 °C behind a blast shield for 16 hours.  The reaction mixture was cooled to room temperature, diluted with ethyl acetate (40 mL), and quenched with a solution of saturated sodium bicarbonate (0.5 mL).  The mixture was filtered through celite and eluted with ethyl acetate followed by drying with sodium sulfate.  The mixture was filtered, concentrated in vacuo and purified by flash chromatography (2:98 to 4:96, EtOAc/hexanes) to provide the product as a slightly yellow oil that solidified at –20 °C and remained solid at room temperature (0.55 g, 87% yield).  The purified product slowly oxidizes in the time it takes to characterize; 





2-(Bis(4-(trifluoromethyl)phenyl)phosphanyl)-5-(trifluoromethyl)benzoic acid (S5) 
Compound S4 (0.550 g, 1.05 mmol) was charged into a round bottom flask equipped with a magnetic stir bar and was dissolved in THF (4.2 mL) at room temperature.  Water (4.2 mL) was added to this solution followed by lithium hydroxide monohydrate (0.882 g, 21.0 mmol).  The reaction mixture was sealed with a Teflon cap, stirred and heated to 70 °C for 12 hours.  The mixture was cooled to room temperature and diluted with ethyl acetate (50 mL).  This mixture was added to a 10% aqueous citric acid solution (50 mL) and this phase was extracted with ethyl acetate (2 x 50 mL).  The combined organic phases were washed with brine, dried with sodium sulfate, filtered and concentrated in vacuo.  The crude material was purified by flash chromatography (3:97 to 5:95, MeOH:CH2Cl2) to provide the product as a white amorphous solid (0.492 g, 92% yield); 1H NMR (300 MHz, CD3OD) δ 8.39 (s, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.68 (d, J = 8.0 Hz, 4H), 7.43 (t, J = 7.6 Hz, 4H), 7.07 (dd, J = 8.1, 3.4 Hz, 1H); 13C NMR (126 MHz, CD3OD) δ 168.5 (d, J = 5.1 Hz), 145.4 (d, J = 30.2 Hz), 143.9 (d, J = 14.6 Hz), 137.2 (d, J = 20.7 Hz), 136.0, 135.5 (d, J = 21.6 Hz), 132.1 (q, J = 32.3 Hz), 132.1 (q, J = 33.0 Hz), 129.5 (q, J = 3.4 Hz), 128.7 – 128.5 (m), 126.5 (dq, J = 7.4, 3.7 Hz), 125.5 (q, J = 271.5 Hz), 125.1 (q, J = 271.6 Hz); 19F NMR (282 MHz, cd3od) δ -64.3, -64.5; 31P NMR (121 MHz, MeOD) δ -4.9; IR (Neat Film, NaCl) 1698, 1324, 1127, 832 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C22H11F9O2P [M-H]-: 509.0358, found 509.0369. 
 
Electron deficient C2-symmetric ligand (L7) 







Methyl 2-(di-o-tolylphosphanyl)benzoate (S9) 





2-(Di-o-tolylphosphanyl)benzoic acid (S10) 
Compound S9 (0.238 g, 0.683 mmol) was charged into a round bottom flask equipped with a magnetic stir bar and was dissolved in THF (2.8 mL) at room temperature.  Water (2.8 mL) was added to this solution followed by lithium hydroxide monohydrate (0.574 g, 13.7 mmol).  The reaction mixture was sealed with a Teflon cap, stirred and heated to 70 °C for 12 hours.  The mixture was cooled to room temperature and diluted with ethyl acetate (30 mL).  This mixture was added to a 10% aqueous citric acid solution (50 mL) and this phase was extracted with ethyl acetate (2 x 30 mL).  The combined organic phases were washed with brine, dried with sodium sulfate, filtered and concentrated in vacuo.  The crude material was purified by flash chromatography (40:60, EtOAc:hexanes) to provide the product as a white amorphous solid (0.205 g, 90% yield).  Characterization data matched literature values.[16]  1H-NMR (500 MHz, CDCl3) δ 8.14–8.20 (m, 1H), 7.38–7.45 (m, 2H), 7.18–7.27 (m, 4H), 7.05 (t, J = 7.5 Hz, 2H), 6.96–7.01 (m, 1H), 6.68–6.72 (m, 2H), 2.40 (s, 6H); HRMS (MM: ESI-APCI) m/z calc’d for C21H18O2P [M-H]-: 333.1044, found 333.1050. 
 
Sterically hindered C2-symmetric ligand (L8) 




3.3.2 Exploratory Allylic Alkylation Screen 
Initially, we ran a series of screens to determine the best combination of ligand and solvent that provided the highest %ee for the allylic alkylation.  The following procedure was followed to conduct these screens.  This procedure is similar to that previously used by the Stoltz group.[17] To separate enantiomers, the allylic alkylation products were derivitized using a cross metathesis with Grubbs-second generation catalyst and methyl acrylate.  This procedure is similar to that previously used by the Stoltz group.[18] 
General Screening Procedure (from Table S1 and Table S2):  
In a nitrogen-filled glove box, 38.0 mg Pd(dba)2 was taken up in 10 mL THF.  To each of 16 half-dram vials, 0.5 mL of this solution (1.90 mg Pd(dba)2, 1.65 mol, 0.100 equiv) was added.  The THF was then removed by evacuation using a Genevac centrifugal evaporator within the glove box.  To each of the vials was then added 500 L of the reaction solvent followed by a small stirring bar.  Stock solutions of ligand (0.0165 M) were made in each 
reaction solvent.  From these ligand stock solutions, 250 L (4.13 mol, 0.125 equiv) were added to the corresponding reaction vials.  The resulting catalyst solutions were stirred in the glove box for 30 minutes at the indicated reaction temperature.  Stock solutions of reaction substrate (0.132 M) were made in each reaction solvent.  
To the stirring catalyst solutions were added 250 L (33.0 mol, 1.00 equiv) of the corresponding substrate solution, resulting in a final reaction volume of 1.00 mL (0.033 M with respect to substrate).  The reactions were sealed with a Teflon-lined cap and stirred for the indicated reaction duration.  The reactions were then removed from the glove box, diluted with 1 mL hexanes and filtered through a silica plug, concentrated in vacuo, taken up in CDCl3 and analyzed by crude 1H NMR to determine conversion. 
The crude reaction mixtures in CDCl3 were concentrated in vacuo in half-dram vials and returned to the glove box.  To each half-dram vial was added 500 L of methyl acrylate solution in CH2Cl2 (0.66 M, 0.33 mmol, 10 equiv) was added, followed by a small stir bar.  The reactions were stirred for approximately 15 minutes.  To the resulting 
solutions were added 500 L each of a Grubb’s second-generation Ru catalyst solution in CH2Cl2 (0.004 M, 2 mol, 0.06 equiv).  The reactions were then stirred at 40 °C for 3 hours, removed from the glove box, filtered through a silica plug, concentrated in vacuo and analyzed by crude 1H NMR to determine conversion and chiral SFC to determine enantiomeric excess.  SFC conditions for each substrate can be found in a table at the end of the text portion of the SI. 
 
2.3.2.1  Characterization data for 5ab and 5c 
 
3-(2-Allyl-2-methylhexanoyl)oxazolidin-2-one (5ab) 
Prepared from 3a or 3b and L6 (Table S1, entries 6, 7, 13, 14): 






Prepared from 3c and L6 (Table S1, entry 16): 
1H NMR (500 MHz, CDCl3) δ 7.88 – 7.82 (m, 1H), 7.24 – 7.17 (m, 3H), 5.80 – 5.68 (m, 1H), 5.12 – 5.03 (m, 1H), 5.05 – 5.00 (m, 1H), 2.97 (dd, J = 14.1, 7.4 Hz, 1H), 2.48 (dd, J = 14.1, 7.3 Hz, 1H), 2.18 (td, J = 12.6, 11.4, 4.3 Hz, 1H), 1.78 (td, J = 14.1, 3.8 Hz, 1H), 1.43 (s, 3H), 1.35 – 1.23 (m, 3H), 1.23 – 1.11 (m, 1H), 0.87 (t, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 177.3, 150.5, 143.0, 133.9, 129.4, 125.0, 124.6, 118.7, 116.1, 109.9, 50.5, 41.2, 36.1, 27.0, 23.3, 22.4, 14.1; IR (Neat Film, NaCl) 2958, 2932, 1795, 1479, 1299, 1027, 757 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C17H22NO3 [M+H]+: 288.1600, found 288.1603. 
 
3.3.2.2  Characterization data for 6ab and 6c. 
 
Methyl (E)-5-methyl-5-(2-oxooxazolidine-3-carbonyl)non-2-enoate (6ab) 
Prepared from 3ab and L6 (Table S1, entries 6, 7, 13, 14): 
1H NMR (500 MHz, CDCl3) δ 6.85 (dt, J = 15.4, 7.7 Hz, 1H), 5.86 (dt, J = 15.5, 1.4 Hz, 1H), 4.40 (t, J = 8.0 Hz, 2H), 4.04 (t, J = 8.0 Hz, 2H), 3.71 (s, 3H), 3.01 (ddd, J = 14.5, 7.6, 1.5 Hz, 1H), 2.51 (ddd, J = 14.5, 7.9, 1.4 Hz, 1H), 2.01 (ddd, J = 13.8, 11.9, 4.8 Hz, 1H), 1.76 (ddd, J = 13.8, 12.1, 4.7 Hz, 1H), 1.34 (s, 3H), 1.31 – 1.24 (m, 2H), 1.24 – 1.07 (m, 2H), 0.87 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 176.7, 166.8, 152.5, 145.4, 123.9, 62.4, 51.6, 49.0, 45.4, 39.8, 35.8, 27.0, 23.2, 22.4, 14.1; IR (Neat Film, NaCl) 2931, 2957, 1778, 1723, 1688, 1274, 1197 cm-1; HRMS (FAB+) m/z calc’d for C15H24NO5 [M+H]+: 298.1654, found 298.1650. 
 
Methyl (E)-5-methyl-5-(2-oxo-2,3-dihydrobenzo[d]oxazole-3-carbonyl)non-2-enoate (6c) 
Prepared from 3c and L6 (Table S1, entry 16): 





3.3.3 Allylic Alkylation Substrate Library  
 
Representative Procedure H. (Compounds 5) 
Unless otherwise noted, the allylic alkylation reactions proceeded as follows: Outside of a glove box, an oven-dried 
2-dram vial equipped with a magnetic stir bar was charged with Pd(dba)2 (2.3 mg, 4.0 mol, 4 mol %).  A second oven-dried two-dram vial was charged with allylenolcarbonate 3d–3q (0.1 mmol).  Finally, a third oven-dried 2-
dram vial was charged with C-2 symmetric ligand L6 or L7 (7.0 mol).  These three uncapped vials were brought into a nitrogen-filled glove box through a small antechamber with 4 x 5 minute vacuum cycles with nitrogen back-filling.  To the vial containing compounds 3d–3q was added or THF (0.3 mL) unless otherwise noted.  To the vial containing C-2 symmetric ligand (L6 or L7) was added THF (0.3 ml) unless otherwise noted.  To the vial containing Pd(dba)2 and a magnetic stir bar was added the entirety of the ligand solution and the reaction was capped, cooled to 20 °C and stirred for 30 min to form the catalyst.  At this time, the entirety of the solution containing the substrate (3d–3q) were added to the catalyst mixture dropwise and the reactions were allowed to stir at 20 °C for 24h.  The reaction mixtures were removed from the glove box through the small antechamber and diluted with hexanes (1mL).  The mixture was filtered through a short plug of silica gel and eluted with ethyl acetate.  The crude material was concentrated and purified by preparative TLC (EtOAc:hexanes mixtures) to provide the products as clear to slightly yellow oils (53–88% yield).  Purified products were converted to the corresponding methyl acrylate species via cross metathesis for SFC analysis. 
 
Methyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5d) 
Representative Procedure H.  Compound 5d was prepared from allylenolcarbonate 3d using General Procedure G (27.0 mg, 85% yield); 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.20 (m, 5H), 5.63 – 5.53 (m, 1H), 5.03 – 4.93 (m, 2H), 4.76 (s, 2H), 3.76 (s, 3H), 2.58 (ddt, J = 13.7, 7.2, 1.3 Hz, 1H), 2.27 (ddt, J = 13.7, 7.6, 1.2 Hz, 1H), 1.78 (ddd, J = 13.4, 12.3, 4.5 Hz, 1H), 1.52 (ddd, J = 13.3, 12.4, 4.5 Hz, 1H), 1.27 – 1.14 (m, 2H), 1.19 (s, 3H), 1.16 – 1.04 (m, 1H), 1.06 – 0.91 (m, 1H), 0.83 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.9, 155.6, 137.8, 134.6, 128.5, 128.3, 127.5, 117.8, 53.5, 50.6, 50.54, 44.1, 39.6, 26.8, 23.4, 22.5, 14.1; IR (Neat Film, NaCl) 2932, 2872, 1738, 1681, 1444, 1156, 998, 916 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C19H28NO3 [M+H]+: 318.2064, found 318.2064; [α]25 –2.36 (c 2.40, CHCl3, 92% ee). 
 
Ethyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5e) 





tert-Butyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5f) 
Representative Procedure H.  Compound 5f was prepared from allylenolcarbonate 3f using General Procedure G (10.8 mg, 88% yield, 0.034mmol scale): 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.19 (m, 5H), 5.73 – 5.60 (m, 1H), 5.07 – 4.95 (m, 2H), 4.71 (s, 2H), 2.66 (ddt, J = 13.6, 7.2, 1.3 Hz, 1H), 2.32 (ddt, J = 13.5, 7.6, 1.2 Hz, 1H), 1.84 (ddd, J = 13.3, 12.0, 4.4 Hz, 1H), 1.56 (ddd, J = 13.2, 12.4, 4.5 Hz, 1H), 1.36 (s, 9H), 1.28 – 1.20 (m, 2H), 1.26 (s, 3H), 1.20 – 1.12 (m, 1H), 1.07 (dddd, J = 15.0, 12.6, 7.3, 4.3 Hz, 1H), 0.85 (t, J = 7.2 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 183.3, 153.9, 138.5, 134.9, 128.4, 128.1, 127.3, 117.7, 82.7, 50.8, 50.3, 44.1, 39.5, 27.9, 26.9, 23.4, 22.5, 14.2; IR (Neat Film, NaCl) 2958, 2931, 2872, 1736, 1682, 1368, 1212, 987, 699 cm-1; HRMS (FAB+) m/z calc’d for C22H34NO3 [M+H]+: 360.2539, found 360.2527; [α]25 -2.89 (c 0.8, CHCl3, 90% ee). 
 
Benzyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5g) 
Representative Procedure H.  Compound 5g was prepared from allylenolcarbonate 3g using General Procedure G (21.0 mg, 53% yield); 1H NMR (500 MHz, CDCl3) δ 7.35 –7.31 (m, 3H), 7.28 – 7.20 (m, 7H), 5.61 – 5.51 (m, 1H), 5.15 (s, 2H), 4.97 – 4.93 (m, 1H), 4.93 – 4.91 (m, 1H), 4.78 (s, 2H), 2.58 (ddt, J = 13.6, 7.1, 1.2 Hz, 1H), 2.25 (ddt, J = 13.6, 7.7, 1.2 Hz, 1H), 1.75 (ddd, J = 13.3, 12.1, 4.4 Hz, 1H), 1.50 (ddd, J = 13.3, 12.4, 4.4 Hz, 1H), 1.18 (s, 3H), 1.16 – 1.12 (m, 2H), 1.10 – 1.02 (m, 1H), 1.02 – 0.91 (m, 1H), 0.80 (t, J = 7.2 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 183.1, 155.0, 137.9, 135.0, 134.6, 128.7, 128.7, 128.7, 128.5, 128.3, 127.5, 117.8, 68.7, 50.7, 50.6, 44.0, 39.4, 26.8, 23.3, 22.5, 14.1; IR (Neat Film, NaCl) 3067, 2957, 2932, 2872, 1732, 1696, 1456, 1386, 1347, 1192 cm-
1; HRMS (MM: ESI-APCI) m/z calc’d for C25H32NO3 [M+H]+: 394.2377, found 394.2376; [α]25 
 
–3.88 (c 1.91, 
CHCl3, 93% ee). 
 
Methyl (R)-(2-allyl-2-methylhexanoyl)(4-chlorophenyl)carbamate (5h) 





Methyl (R)-(2-allyl-2-methyloctanoyl)(benzyl)carbamate (5i) 
Representative Procedure H.  Compound 5i was prepared from allylenolcarbonate 3i using General Procedure G (24.0 mg, 69% yield); 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.27 (m, 3H), 7.26 – 7.22 (m, 2H), 5.58 (ddt, J = 17.3, 10.1, 7.3 Hz, 1H), 5.02 – 4.94 (m, 2H), 4.76 (s, 2H), 3.76 (s, 3H), 2.58 (ddt, J = 13.7, 7.0, 1.2 Hz, 1H), 2.27 (ddt, J = 13.6, 7.6, 1.2 Hz, 1H), 1.77 (ddd, J = 13.3, 12.0, 4.4 Hz, 1H), 1.51 (ddd, J = 13.3, 12.0, 4.4 Hz, 1H), 1.19 (s, 3H), 1.28 – 1.14 (m, 6H), 1.16 – 1.06 (m, 1H), 1.05 – 0.95 (m, 1H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.88, 155.63, 137.81, 134.58, 128.45, 128.30, 127.49, 117.79, 53.54, 50.60, 50.57, 44.12, 39.90, 31.79, 29.97, 24.52, 22.73, 22.45, 14.22; IR (Neat Film, NaCl) 3067, 2950, 2930, 2858, 1738, 1694, 1455, 1445, 1351, 1208, 1000 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C21H32NO3 [M+H]+: 346.2377, found 346.2375; [α]25 
 
–2.14 (c 
2.18, CHCl3, 94% ee). 
 
Methyl (S)-benzyl(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-methylpent-4-enoyl)carbamate (5j) 
Representative Procedure H.  Compound 5j was prepared from allylenolcarbonate 3j using General Procedure G (32.1 mg, 76% yield); 1H NMR (500 MHz, CDCl3) δ 7.29 – 7.18 (m, 5H), 5.52 (ddt, J = 17.2, 10.1, 7.3 Hz, 1H), 4.99 – 4.90 (m, 2H), 4.74 (s, 2H), 3.73 (s, 3H), 3.54 – 3.44 (m, 2H), 2.58 (dd, J = 13.6, 7.1 Hz, 1H), 2.27 (dd, J = 13.6, 7.5 Hz, 1H), 2.11 – 2.03 (m, 1H), 1.84 – 1.76 (m, 1H), 1.20 (s, 3H), 0.83 (d, J = 0.7 Hz, 9H), -0.03 (d, J = 1.8 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 182.1, 155.5, 137.8, 134.3, 128.5, 128.2, 127.5, 118.1, 59.9, 53.6, 50.6, 49.2, 44.5, 41.9, 26.1, 22.7, 18.4, –5.2, –5.2;  IR (Neat Film, NaCl) 2955, 2929, 2857, 1741, 1686, 1444, 1351, 1207, 1095, 837 cm-1; HRMS (FAB+) m/z calc’d for C23H38NO3 [M+H]+: 420.2570, found 420.2541; [α]25 
 
– 6.23 
(c 2.91, CHCl3, 94% ee). 
 
Methyl (S)-benzyl(2-methyl-2-phenylpent-4-enoyl)carbamate (5k) 
Representative Procedure H.  Compound 5k was prepared from allylenolcarbonate 3k using General Procedure G (26.0 mg, 77% yield); 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.30 (m, 4H), 7.30 – 7.23 (m, 3H), 7.20 – 7.15 (m, 1H), 7.06 – 7.01 (m, 2H), 5.34 (dddd, J = 16.8, 10.3, 8.1, 6.5 Hz, 1H), 4.95 (ddt, J = 8.7, 2.2, 1.2 Hz, 1H), 4.93 (h, J = 1.2 Hz, 1H), 4.88 (s, 2H), 3.22 (s, 3H), 2.90 (ddt, J = 13.7, 8.2, 1.0 Hz, 1H), 2.55 (ddt, J = 13.6, 6.6, 1.4 Hz, 1H), 1.63 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 179.7, 154.5, 143.7, 137.5, 134.3, 128.6, 128.5, 128.1, 127.6, 126.2, 125.9, 118.5, 54.0, 53.3, 50.1, 47.0, 23.8; IR (Neat Film, NaCl) 3064, 3007, 2954, 1755, 1674 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C21H23NO3 [M+H]+: 338.1751, found 338.1754; [α]25 
 





Methyl (R)-(2-allyl-2-ethylhexanoyl)(benzyl)carbamate (5l) 
Representative Procedure H.  Compound 5l was prepared from allylenolcarbonate 3l using General Procedure G (8.6 mg, 76% yield, 0.034 mmol scale).  Note: this reaction was run in EtOAc and not THF; 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.20 (m, 5H), 5.62 (ddt, J = 17.3, 10.1, 7.3 Hz, 1H), 5.07 – 4.97 (m, 2H), 4.78 (s, 2H), 3.75 (s, 3H), 2.53 – 2.39 (m, 2H), 1.82 – 1.55 (m, 4H), 1.28 – 1.18 (m, 2H), 1.15 – 1.00 (m, 2H), 0.85 (t, J = 7.3 Hz, 3H), 0.76 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 181.7, 155.6, 137.9, 134.7, 128.5, 128.3, 127.5, 117.7, 54.0, 53.6, 50.8, 39.1, 35.0, 28.1, 26.7, 23.4, 14.1, 9.0; IR (Neat Film, NaCl) 2958, 2933, 2873, 1741, 1732, 1682, 1443, 1350, 1206, 699 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C20H29NO3 [M+H]+: 332.2220, found 332.2216; [α]25 +0.64 (c 0.7, CHCl3, 82% ee). 
 
Methyl (R)-(2-allyl-2-ethyloctanoyl)(benzyl)carbamate (5m) 




Methyl (S)-(2-allyl-2-(3-phenylpropyl)octanoyl)(benzyl)carbamate (5n) 






Representative Procedure H.  Compound 5o was prepared from allylenolcarbonate 3o using General Procedure G (16.3 mg, 67% yield); 1H NMR (500 MHz, CDCl3) δ 5.69 (ddt, J = 17.4, 10.1, 7.4 Hz, 1H), 5.11 – 5.01 (m, 2H), 4.38 (dd, J = 8.4, 7.6 Hz, 2H), 4.04 (dd, J = 8.5, 7.6 Hz, 2H), 2.68 – 2.54 (m, 2H), 2.05 – 1.76 (m, 4H), 1.33 – 1.23 (m, 2H), 1.21 – 1.04 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H), 0.80 (t, J = 7.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 177.5, 152.4, 134.5, 117.9, 62.3, 52.7, 45.6, 36.6, 31.8, 26.6, 25.1, 23.3, 14.2, 8.8; IR (Neat Film, NaCl) 3076, 2960, 2931, 2874, 1778, 1682, 1468, 1384, 1202 cm-1; HRMS (FAB+) m/z calc’d for C14H24NO3 [M+H]+: 254.1756, found 254.1756; [α]25 
 
0.02 (c 1.45, CHCl3, 69% ee). 
 
(R)-3-(2-Allyl-2-ethyloctanoyl)oxazolidin-2-one (5p) 




3.3.4  Cross Metathesis Procedure 
 
Representative Procedure I. (Compounds 6) 





Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6d) 
Representative Procedure I.  Compound 6d was prepared using General Procedure H with 5d (26.9 mg, 85 mol) to afford a clear oil (25.5 mg, 80% yield): 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.19 (m, 5H), 6.83 (dt, J = 15.5, 7.7 Hz, 1H), 5.81 (dt, J = 15.5, 1.4 Hz, 1H), 4.77 (s, 2H), 3.76 (s, 3H), 3.71 (s, 3H), 2.76 (ddd, J = 14.0, 7.6, 1.5 Hz, 1H), 2.44 (ddd, J = 14.0, 7.9, 1.4 Hz, 1H), 1.77 (ddd, J = 13.4, 12.2, 4.4 Hz, 1H), 1.55 (ddd, J = 13.4, 12.4, 4.6 Hz, 1H), 1.23 (s, 3H), 1.22 – 1.15 (m, 2H), 1.12 – 1.01 (m, 1H), 0.96 (ttd, J = 11.9, 7.4, 4.4 Hz, 1H), 0.81 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.0, 166.7, 155.5, 145.5, 137.6, 128.5, 128.2, 127.6, 123.8, 53.7, 51.6, 50.6, 50.6, 42.3, 39.7, 26.8, 23.3, 22.4, 14.1; IR (Neat Film, NaCl) 2957, 2872, 1726, 1686, 1439, 1350, 1272, 1195, 998 cm-1; HRMS (ESI) m/z calc’d for C21H33N2O5 [M+NH4]+: 393.2384, found 393.2376; [α]25 +12.17 (c 2.3, CHCl3, 92% ee). 
 
Methyl (R,E)-5-(benzyl(ethoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6e) 
Representative Procedure I.  Compound 6e was prepared using General Procedure H with 5e (17.4 mg, 53 mol) to afford a clear oil (17.4 mg, 85% yield): 1H NMR (500 MHz, CDCl3) δ 7.33 – 7.19 (m, 5H), 6.84 (dt, J = 15.5, 7.7 Hz, 1H), 5.82 (dt, J = 15.5, 1.4 Hz, 1H), 4.77 (s, 2H), 4.25 – 4.12 (m, 2H), 3.71 (s, 3H), 2.78 (ddd, J = 13.9, 7.5, 1.5 Hz, 1H), 2.46 (ddd, J = 13.9, 7.9, 1.4 Hz, 1H), 1.80 (ddd, J = 13.4, 12.3, 4.4 Hz, 1H), 1.63 – 1.52 (m, 1H), 1.25 (s, 3H), 1.24 (t, J = 9.1, 3H), 1.23 – 1.16 (m, 2H), 1.14 – 1.03 (m, 1H), 0.98 (ttd, J = 12.4, 7.5, 4.4 Hz, 1H), 0.82 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.1, 166.8, 155.1, 145.6, 137.8, 128.5, 128.2, 127.5, 123.8, 63.1, 51.6, 50.6, 50.5, 42.2, 39.6, 26.8, 23.3, 22.5, 14.3, 14.1; IR (Neat Film, NaCl) 1956, 2873, 1727, 1688, 1436, 1376, 1345, 1272, 1193, 1019, 986 cm-1; HRMS (ESI) m/z calc’d for C22H35N2O5 [M+NH4]+: 407.2540, found 407.2538; [α]25 +9.70 (c 1.5, CHCl3, 94% ee). 
 
Methyl (R,E)-5-(benzyl(tert-butoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6f) 





Methyl (R,E)-5-(benzyl((benzyloxy)carbonyl)carbamoyl)-5-methylnon-2-enoate (6g) 
Representative Procedure I.  Compound 6g was prepared using General Procedure H with 5g (20.9 mg, 53 mol) to afford a clear oil (18.2 mg, 76% yield): 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.31 (m, 3H), 7.29 – 7.20 (m, 7H), 6.81 (dt, J = 15.4, 7.7 Hz, 1H), 5.75 (dd, J = 15.5, 1.4 Hz, 1H), 5.15 (s, 2H), 4.79 (s, 2H), 3.71 (s, 3H), 2.73 (ddd, J = 14.0, 7.6, 1.4 Hz, 1H), 2.43 (ddd, J = 13.9, 7.9, 1.5 Hz, 1H), 1.76 (ddd, J = 13.5, 12.2, 4.5 Hz, 1H), 1.61 – 1.48 (m, 1H), 1.22 (s, 3H), 1.14 (p, J = 7.2 Hz, 2H), 1.10 – 0.99 (m, 1H), 0.94 (ttd, J = 12.3, 7.4, 4.3 Hz, 1H), 0.79 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.2, 166.8, 154.9, 145.5, 137.7, 134.9, 128.8, 128.8, 128.7, 128.5, 128.2, 127.5, 123.8, 68.9, 51.6, 50.6, 50.5, 42.1, 39.5, 26.8, 23.2, 22.5, 14.1; IR (Neat Film, NaCl) 2955, 1725, 1688, 1386, 1346, 1272, 1192, 990, 698 cm-1; HRMS (ESI) m/z calc’d for C27H37N2O5 [M+NH4]+: 469.2697, found 469.2693; [α]25 +5.94 (c 1.7, CHCl3, 93% ee). 
 
Methyl (R,E)-5-((4-chlorophenyl)(methoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6h) 
Representative Procedure I.  Compound 6h was prepared using General Procedure H with 5h (19.8 mg, 59 mol) to afford a clear oil (19.7 mg, 80% yield): 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.31 (m, 2H), 7.13 – 7.05 (m, 2H), 6.88 (dt, J = 15.4, 7.7 Hz, 1H), 5.83 (dt, J = 15.3, 1.3 Hz, 1H), 3.74 (s, 3H), 3.73 (s, 3H), 2.73 (ddd, J = 14.3, 7.6, 1.5 Hz, 1H), 2.44 (ddd, J = 14.1, 7.8, 1.4 Hz, 1H), 1.79 – 1.67 (m, 1H), 1.61 – 1.52 (m, 1H), 1.30 – 1.14 (m, 4H), 1.24 (s, 3H), 0.86 (t, J = 6.8 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 181.7, 166.7, 154.7, 144.8, 136.9, 134.1, 129.5, 129.3, 124.2, 54.0, 51.7, 51.2, 41.8, 39.4, 26.6, 23.2, 22.9, 14.1; IR (Neat Film, NaCl) 2956, 2873, 1728, 1658, 1492, 1439, 1272, 1247, 1198, 1092 cm-1; HRMS (FAB+) m/z calc’d for C20H26NClO5 [M+H-H2]+: 395.1499, found 395.1476; [α]25 +7.94 (c 1.8, CHCl3, 90% ee). 
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-methylundec-2-enoate (6i) 





Methyl (S,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-7-((tert-butyldimethylsilyl)oxy)-5-methylhept-2-enoate (6j) 
Representative Procedure I.  Compound 6j was prepared using General Procedure H with 5j (31.7 mg, 76 mol) to afford a clear oil (28.5 mg, 79% yield): 1H NMR (500 MHz, CDCl3) δ 7.29 – 7.17 (m, 5H), 6.79 (dq, J = 15.4, 7.8 Hz, 1H), 5.77 (dt, J = 15.5, 1.4 Hz, 1H), 4.75 (s, 2H), 3.72 (s, 3H), 3.67 (s, 3H), 3.54 – 3.44 (m, 2H), 2.78 (ddd, J = 14.0, 7.6, 1.5 Hz, 1H), 2.47 (ddd, J = 14.0, 7.9, 1.5 Hz, 1H), 2.06 (ddd, J = 13.9, 7.8, 6.2 Hz, 1H), 1.86 (ddd, J = 13.9, 7.9, 6.3 Hz, 1H), 1.24 (s, 3H), 0.82 (s, 9H), -0.03 (s, 3H), -0.03 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 181.2, 166.7, 155.4, 145.3, 137.6, 128.6, 128.1, 127.6, 124.0, 59.8, 53.7, 51.6, 50.6, 49.3, 42.6, 41.8, 26.1, 22.7, 18.4, -5.2, -5.3; IR (Neat Film, NaCl) 2955, 2857, 1728, 1688, 1440, 1351, 1256, 1195, 1094, 994 cm-1; HRMS (FAB+) m/z calc’d for C25H40NO6Si [M+H]+: 478.2625, found 478.2646; [α]25 +2.20 (c 2.6, CHCl3, 94% ee). 
 
Methyl (S,E)-6-(benzyl(methoxycarbonyl)amino)-5-methyl-6-oxo-5-phenylhex-2-enoate (6k) 
Representative Procedure I.  Compound 6k was prepared using General Procedure H with 4k (26.0 mg, 77 mol) to afford a clear oil (23.9 mg, 78% yield): 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.30 (m, 4H), 7.30 – 7.23 (m, 3H), 7.22 – 7.13 (m, 1H), 7.05 – 6.97 (m, 2H), 6.57 (ddd, J = 15.4, 8.3, 6.9 Hz, 1H), 5.71 (dt, J = 15.5, 1.4 Hz, 1H), 4.89 (s, 2H), 3.67 (s, 3H), 3.22 (s, 3H), 3.01 (ddd, J = 13.9, 8.4, 1.2 Hz, 1H), 2.67 (ddd, J = 13.9, 6.9, 1.6 Hz, 1H), 1.68 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 179.0, 166.6, 154.3, 145.1, 142.7, 137.4, 128.5, 128.5, 128.3, 127.7, 126.6, 125.8, 124.3, 54.1, 53.4, 51.5, 50.1, 45.9, 23.4; IR (Neat Film, NaCl) 2953, 1725, 1674, 1496, 1441, 1351, 1315, 1274, 1203, 1004, 700 cm-1; HRMS (ESI) m/z calc’d for C23H29N2O5 [M+NH4]+: 413.2071, found 413.2065; [α]25 +67.74 (c 2.2, CHCl3, 76% ee). 
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-ethylnon-2-enoate (6l) 






Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-ethylundec-2-enoate (6m) 
Representative Procedure I.  Compound 6m was prepared using General Procedure H with 5m (19.0 mg, 53 mol) to afford a clear oil (18.7 mg, 85% yield): 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.14 (m, 5H), 6.83 (dt, J = 15.4, 7.7 Hz, 1H), 5.83 (dd, J = 15.5, 1.6 Hz, 1H), 4.79 (s, 2H), 3.75 (s, 3H), 3.72 (s, 3H), 2.62 (qdd, J = 14.6, 7.7, 1.5 Hz, 2H), 1.84 (dq, J = 14.8, 7.4 Hz, 1H), 1.78 – 1.70 (m, 1H), 1.69 – 1.54 (m, 2H), 1.30 – 1.15 (m, 6H), 1.15 – 0.97 (m, 2H), 0.86 (t, J = 7.0 Hz, 3H), 0.75 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 180.8, 166.8, 155.5, 145.8, 137.7, 128.5, 128.2, 127.5, 123.6, 54.2, 53.7, 51.6, 50.7, 37.6, 35.5, 31.7, 29.9, 28.3, 24.5, 22.7, 14.2, 9.0; IR (Neat Film, NaCl) 2955, 1727, 1683, 1441, 1351, 1176 cm-1; HRMS (ESI) m/z calc’d for C25H39N2O5 [M+NH4]+: 435.2853, found 435.2853; [α]25 +2.25 (c 1.7, CHCl3, 93% ee). 
 
Methyl (S,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-(3-phenylpropyl)undec-2-enoate (6n) 
Representative Procedure I.  Compound 6n was prepared using General Procedure H with 5n (21.6 mg, 48 mol) to afford a clear oil (19.8 mg, 84% yield): 1H NMR (500 MHz, CDCl3) δ 7.30 – 7.14 (m, 8H), 7.13 – 7.07 (m, 2H), 6.79 (dt, J = 15.4, 7.6 Hz, 1H), 5.79 (dt, J = 15.4, 1.3 Hz, 1H), 4.78 (s, 2H), 3.72 (s, 3H), 3.67 (s, 3H), 2.60 (dt, J = 7.7, 1.3 Hz, 2H), 2.53 (t, J = 7.4 Hz, 2H), 1.84 – 1.68 (m, 2H), 1.65 – 1.51 (m, 2H), 1.51 – 1.35 (m, 2H), 1.29 – 1.13 (m, 6H), 1.12 – 0.93 (m, 2H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 180.6, 166.7, 155.4, 145.6, 142.1, 137.6, 128.5, 128.5, 128.4, 128.2, 127.6, 125.9, 123.7, 53.8, 53.7, 51.6, 50.7, 38.2, 36.3, 35.8, 35.2, 31.7, 29.9, 26.3, 24.4, 22.7, 14.2; IR (Neat Film, NaCl) 3028, 2930, 2858, 1727, 1683, 1442, 1350, 1273, 1170, 699 cm-1; HRMS (ESI) m/z calc’d for C31H45N2O5 [M+NH4]+: 525.3323, found 525.3329; [α]25 +0.25 (c 1.8, CHCl3, 76% ee). 
 
Methyl (R,E)-5-ethyl-5-(2-oxooxazolidine-3-carbonyl)non-2-enoate (6o) 





Methyl (R,E)-5-ethyl-5-(2-oxooxazolidine-3-carbonyl)undec-2-enoate (6p) 















To an oven-dried round-bottom flask and magnetic stir bar was added 5j (60 mg, 0.143 mmol) followed by anhydrous THF (1.4 mL).  The solution was stirred under nitrogen at room temperature.  A solution of NaOH in anhydrous methanol (0.17 mL, 1.0 M) was added dropwise by syringe.  The reaction was stirred at room temperature for 45 min.  Afterward, the reaction mixture was diluted with ethyl acetate and quenched with water.  The mixture was partitioned between water and ethyl acetate and the aqueous layer was extracted two additional times with ethyl acetate.  The combined organic layers were washed with brine (50 mL), dried with sodium sulfate and filtered.  This mixture was concentrated in vacuo and purified by flash chromatography (10/90 to 12/88 EtOAc/hexanes) to provide the product as an amorphous white solid (30.2 mg, 58% yield); 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.24 (m, 5H), 6.37 (s, 1H), 5.80 – 5.69 (m, 1H), 5.08 – 5.06 (m, 1H), 5.06 – 5.03 (m, 1H), 4.49 – 4.38 (m, 2H), 3.68 (td, J = 6.7, 1.5 Hz, 2H), 2.40 (ddt, J = 13.7, 7.1, 1.2 Hz, 1H), 2.27 (ddt, J = 13.7, 7.7, 1.1 Hz, 1H), 1.93 (dt, J = 13.7, 6.7 Hz, 1H), 1.69 (dt, J = 14.1, 6.7 Hz, 1H), 1.20 (s, 3H), 0.86 (s, 9H), 0.02 – -0.00 (m, 6H); 







To an oven-dried 2-dram vial and magnetic stir bar was added S11 (30 mg, 0.083 mmol) followed by anhydrous THF (0.5 mL).  The solution was stirred under nitrogen at room temperature.  A solution of TBAF in anhydrous THF (0.17 mL, 1.0 M) was added dropwise by syringe.  The reaction was stirred at room temperature for 2 h.  Afterward, the reaction mixture was quenched with saturated ammonium chloride.  The mixture was partitioned between water and dichloromethane and the aqueous layer was extracted two additional times with dichloromethane.  The combined organic layers were washed with brine (50 mL), dried with sodium sulfate and filtered.  This mixture was concentrated in vacuo and purified by flash chromatography (60/40 EtOAc/hexanes) to provide the product as an oil (19.5 mg, 58% yield): 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.24 (m, 5H), 6.10 (s, 1H), 5.78 – 5.69 (m, 1H), 5.11 – 5.09 (m, 1H), 5.09 – 5.05 (m, 1H), 4.45 (d, J = 5.5 Hz, 2H), 3.78 (dt, J = 11.8, 6.1 Hz, 1H), 3.74 – 3.65 (m, 1H), 2.56 (s, 1H), 2.48 (ddt, J = 13.7, 7.0, 1.3 Hz, 1H), 2.22 (ddt, J = 13.7, 7.7, 1.2 Hz, 1H), 2.00 (ddd, J = 14.4, 7.3, 5.5 Hz, 1H), 1.70 (ddd, J = 14.4, 6.6, 5.4 Hz, 1H), 1.22 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 177.5, 138.3, 133.7, 128.9, 127.9, 127.7, 118.9, 59.3, 44.5, 44.4, 44.0, 41.5, 22.2; IR (Neat Film, NaCl) 3335, 2927, 1634, 1538, 1249 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C15H21NO2 [M+H]+: 248.1645, found 248.1651; [α]25 –61.06 (c 1.63, CHCl3, 94% ee). 
 
(S)-3-Allyl-1-benzyl-3-methylpyrrolidin-2-one ((S)-8) 
To an oven-dried 2-dram vial and magnetic stir bar was added S12 (19.5 mg, 0.079 mmol) followed by anhydrous 






To a round-bottom flask and magnetic stir bar was added 7[17] (98% ee) (80 mg, 0.33 mmol) followed by MeOH (4.0 mL).  The solution was stirred under nitrogen at 0 °C.  A solution of NaOH (0.61 mL, 2.0 M, 1.2 mmol) was added dropwise by syringe.  The reaction was stirred at 0 °C for 1.5 h.  The mixture was partitioned between brine and diethyl ether.  The organic layer was washed with saturated sodium bicarbonate solution followed by brine, dried with sodium sulfate and filtered.  This mixture was concentrated in vacuo and purified by flash chromatography (80/20 to 100/0 EtOAc/hexanes) to provide the product as an amorphous white solid (28.3 mg, 62% yield); 1H NMR (500 MHz, CDCl3) δ 6.49 (s, 1H), 5.84 – 5.70 (m, 1H), 5.13 – 5.09 (m, 1H), 5.08 (p, J = 1.2 Hz, 1H), 3.34 – 3.19 (m, 2H), 2.33 – 2.25 (m, 1H), 2.19 (ddt, J = 13.6, 8.2, 1.1 Hz, 1H), 2.15 – 2.06 (m, 1H), 1.86 – 1.76 (m, 1H), 1.15 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 182.9, 134.1, 118.4, 43.1, 42.0, 39.0, 33.0, 22.8; IR (Neat Film, NaCl) 3233, 3077, 2928, 1697, 1295, 915 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C8H14NO [M+H]+: 140.1070, found 140.1071; [α]25 –33.10 (c 2.27, CHCl3, 98% ee). 
 
(R)-3-Allyl-1-benzyl-3-methylpyrrolidin-2-one ((R)-8): 
To an oven-dried 2-dram vial and magnetic stir bar was added S13 (28.3 mg, 0.203 mmol) followed by anhydrous DMF (1.0 mL).  The solution was stirred under nitrogen at 0 °C.  Sodium hydride (8.1 mg, 0.203 mmol) was added portion-wise over two minutes.  The reaction was stirred at 0 °C for 40 min.  To this solution was added benzyl 
bromide (30 L, 0.256 mmol) dropwise through by syringe.  This solution was warmed to room temperature and stirred for 2 h.  Afterward, the reaction mixture was quenched with saturated ammonium chloride.  The mixture was partitioned between water and ethyl acetate and the aqueous layer was extracted two additional times with ethyl acetate.  The combined organic layers were washed with brine (50 mL), dried with sodium sulfate and filtered.  This mixture was concentrated in vacuo and purified by preparative TLC (40/60 EtOAc/hexanes) to provide the product as an oil (27 mg, 59% yield).  Characterization data matched previously synthesized material;[17] [α]25 –33.10 (c 2.27, CHCl3, 98% ee). 
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3-(Hex-1-yn-1-yl)oxazolidin-2-one  (1a)   
 
 
































































































































pavel400-120, 20130831, CDCl3, p071
S44  
 
3-(Oct-1-yn-1-yl)oxazolidin-2-one  (1q)   
 
 







































































pavel400-77, 20130807, CDCl3, p046


































pavel400-80, 20130809, CDCl3, p046
S45  
 




Ethyl benzyl(hex-1-yn-1-yl)carbamate  (1e)   
 
  






























































































































tert-Butyl benzyl(hex-1-yn-1-yl)carbamate  (1f)   
 
  





























































































































Benzyl benzyl(hex-1-yn-1-yl)carbamate  (1g)   
 
  





















































































































































































pavel400-189, 20140131, p195b, CDCl3





































pavel400-190, 20140202, p195b, CDCl3
S50  
 























































































































































































































Methyl benzyl(phenylethynyl)carbamate  (1k)   
 
 





















































































3-(Hex-1-yn-1-yl)benzo[d]oxazol-2(3H)-one  (1c)   
 
  




































































































































































































































































































































































































































































































































































































































































































































































(E)-Methyl benzyl(4-((tert-butyldimethylsilyl)oxy)-1-iodo-2-methylbut-1-en-1-yl)carbamate (4j) 
 
 

















































































































































































































(E)-Methyl benzyl(2-ethyl-1-iodohex-1-en-1-yl)carbamate (4l) 
 
  



















































































































































































































































































































































(E)-3-(2-Ethyl-1-iodooct-1-en-1-yl)oxazolidin-2-one  (4q)  
 
 







































































































































































































































































































































(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3d)  
  
 








































































































pavel400-40, 20130709, p032-2, CDCl3























































pavel400-41, 20130709, p032-2, CDCl3
S73  
 






























































































































pavel400-10, 20131001, p090-1, CDCl3


























































pavel400-22, 20131007, p090-1e, CDCl3
S74  
 




































































































































pavel400-111, 20131215, p143, CDCl3
S75  
 
(E)-Benzyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3g)  
 
  






































































































































































































































































































































(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-methyloct-1-en-1-yl)(benzyl)carbamate (3i) 
 
 







































































































































































































(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-ethyloct-1-en-1-yl)(benzyl)carbamate (3m)  
 
  






















































































































































































































(E)-Allyl (2-ethyl-1-(2-oxooxazolidin-3-yl)hex-1-en-1-yl) carbonate (3p)  
 
 






















































































































































































































(E)-Allyl (2-ethyl-1-(2-oxooxazolidin-3-yl)oct-1-en-1-yl) carbonate (3q) 
  
 






























































































































































































Methyl 2-bromo-5-(trifluoromethyl)benzoate (S2) 
  















Methyl 2-(bis(4-(trifluoromethyl)phenyl)phosphoryl)-5-(trifluoromethyl)benzoate (S3) 
       














































 13C NMR (126 MHz, CDCl3) of compound S3. 

































 19F NMR (282 MHz, CDCl3) of compound S3. 
 31P NMR (121 MHz, CDCl3) of compound S3. 
S90  
 
Methyl 2-(bis(4-(trifluoromethyl)phenyl)phosphanyl)-5-(trifluoromethyl)benzoate (S4) 
       













































  13C NMR (126 MHz, CDCl3) of compound S4. 

































 19F NMR (282 MHz, CDCl3) of compound S4. 
 31P NMR (121 MHz, CDCl3) of compound S4. 
S93  
 
2-(Bis(4-(trifluoromethyl)phenyl)phosphanyl)-5-(trifluoromethyl)benzoic acid (S5) 
        













































  13C NMR (126 MHz, CDCl3) of compound S5. 

































 19F NMR (282 MHz, CDCl3) of compound S5. 
 31P NMR (121 MHz, CDCl3) of compound S5. 
S96  
 
Electron deficient C2-symmetric ligand (L7)        














































 13C NMR (126 MHz, CDCl3) of compound L7. 

































 19F NMR (282 MHz, CDCl3) of compound L7. 
 31P NMR (121 MHz, CDCl3) of compound L7. 
S99  
 
Methyl 2-(di-o-tolylphosphanyl)benzoate (S9)       













































  13C NMR (126 MHz, CDCl3) of compound S9. 


























 31P NMR (121 MHz, CDCl3) of compound S9. 
S102  
 
Sterically hindered C2-symmetric ligand (L8)        














































 13C NMR (126 MHz, CDCl3) of compound L8. 





















 31P NMR (121 MHz, CDCl3) of compound L8. 
S105  
 
3-(2-Allyl-2-methylhexanoyl)oxazolidin-2-one (5ab)     













































 13C NMR (126 MHz, CDCl3) of compound 5ab. 
Infrared spectrum (Thin Film, NaCl) of compound 5ab. 
S107  
 
Methyl (E)-5-methyl-5-(2-oxooxazolidine-3-carbonyl)non-2-enoate (6ab)     














































 13C NMR (126 MHz, CDCl3) of compound 6ab. 
Infrared spectrum (Thin Film, NaCl) of compound 6ab. 
S109  
 
1-(2-Allyl-2-methylhexanoyl)indolin-2-one (5c)    














































 13C NMR (126 MHz, CDCl3) of compound 5c. 
Infrared spectrum (Thin Film, NaCl) of compound 5c. 
S111  
 
Methyl (E)-5-methyl-5-(2-oxo-2,3-dihydrobenzo[d]oxazole-3-carbonyl)non-2-enoate (6c)  














































 13C NMR (126 MHz, CDCl3) of compound 6c. 
Infrared spectrum (Thin Film, NaCl) of compound 6c. 
S113  
 
Methyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5d)    













































   13C NMR (126 MHz, CDCl3) of compound 5d. 
Infrared spectrum (Thin Film, NaCl) of compound 5d. 
S115  
 
 Ethyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5e)   














































 13C NMR (126 MHz, CDCl3) of compound 5e. 
Infrared spectrum (Thin Film, NaCl) of compound 5e 
S117  
 
tert-Butyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5f)    














































 13C NMR (126 MHz, CDCl3) of compound 5f. 
Infrared spectrum (Thin Film, NaCl) of compound 5f. 
S119  
 
Benzyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5g)   














































 13C NMR (126 MHz, CDCl3) of compound 5g. 
Infrared spectrum (Thin Film, NaCl) of compound 5g. 
S121  
 
Methyl (R)-(2-allyl-2-methylhexanoyl)(4-chlorophenyl)carbamate (5h)    













































 13C NMR (126 MHz, CDCl3) of compound 5h. 
Infrared spectrum (Thin Film, NaCl) of compound 5h. 
S123  
 
Methyl (R)-(2-allyl-2-methyloctanoyl)(benzyl)carbamate (5i)    














































 13C NMR (126 MHz, CDCl3) of compound 5i. 
Infrared spectrum (Thin Film, NaCl) of compound 5i. 
S125  
 
Methyl (S)-benzyl(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-methylpent-4-enoyl)carbamate (5j)   













































 13C NMR (126 MHz, CDCl3) of compound 5j. 
Infrared spectrum (Thin Film, NaCl) of compound 5j. 
S127  
 
Methyl (S)-benzyl(2-methyl-2-phenylpent-4-enoyl)carbamate (5k)  














































 13C NMR (126 MHz, CDCl3) of compound 5k. 
Infrared spectrum (Thin Film, NaCl) of compound 5k. 
S129  
 
Methyl (R)-(2-allyl-2-ethylhexanoyl)(benzyl)carbamate (5l)    











































 13C NMR (126 MHz, CDCl3) of compound 5l. 
Infrared spectrum (Thin Film, NaCl) of compound 5l. 
S131  
 
Methyl (R)-(2-allyl-2-ethyloctanoyl)(benzyl)carbamate (5m)   














































 13C NMR (126 MHz, CDCl3) of compound 5m. 
Infrared spectrum (Thin Film, NaCl) of compound 5m. 
S133  
 
Methyl (S)-(2-allyl-2-(3-phenylpropyl)octanoyl)(benzyl)carbamate (5n)    













































 13C NMR (126 MHz, CDCl3) of compound 5n. 
Infrared spectrum (Thin Film, NaCl) of compound 5n. 
S135  
 
(R)-3-(2-Allyl-2-ethylhexanoyl)oxazolidin-2-one (5o)   
 












































 13C NMR (126 MHz, CDCl3) of compound 5o. 
Infrared spectrum (Thin Film, NaCl) of compound 5o. 
S137  
 
(R)-3-(2-Allyl-2-ethyloctanoyl)oxazolidin-2-one (5p)     












































 13C NMR (126 MHz, CDCl3) of compound 5p. 
Infrared spectrum (Thin Film, NaCl) of compound 5p. 
S139  
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6d)      












































 13C NMR (126 MHz, CDCl3) of compound 6d. 
Infrared spectrum (Thin Film, NaCl) of compound 6d. 
S141  
 
Methyl (R,E)-5-(benzyl(ethoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6e)      













































 13C NMR (126 MHz, CDCl3) of compound 6e. 
Infrared spectrum (Thin Film, NaCl) of compound 6e 
S143  
 
Methyl (R,E)-5-(benzyl(tert-butoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6f)    













































 13C NMR (126 MHz, CDCl3) of compound 6f. 
Infrared spectrum (Thin Film, NaCl) of compound 6f. 
S145  
 
Methyl (R,E)-5-(benzyl((benzyloxy)carbonyl)carbamoyl)-5-methylnon-2-enoate (6g)     














































 13C NMR (126 MHz, CDCl3) of compound 6g. 
Infrared spectrum (Thin Film, NaCl) of compound 6g. 
S147  
 
Methyl (R,E)-5-((4-chlorophenyl)(methoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6h)    














































 13C NMR (126 MHz, CDCl3) of compound 6h. 
Infrared spectrum (Thin Film, NaCl) of compound 6h. 
S149  
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-methylundec-2-enoate (6i)    














































 13C NMR (126 MHz, CDCl3) of compound 6i. 
Infrared spectrum (Thin Film, NaCl) of compound 6i. 
S151  
 
Methyl (S,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-7-((tert-butyldimethylsilyl)oxy)-5-methylhept-2-enoate (6j)   














































 13C NMR (126 MHz, CDCl3) of compound 6j. 
Infrared spectrum (Thin Film, NaCl) of compound 6j. 
S153  
 
Methyl (S,E)-6-(benzyl(methoxycarbonyl)amino)-5-methyl-6-oxo-5-phenylhex-2-enoate (6k)    













































 13C NMR (126 MHz, CDCl3) of compound 6k. 
Infrared spectrum (Thin Film, NaCl) of compound 6k. 
S155  
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-ethylnon-2-enoate (6l)       














































 13C NMR (126 MHz, CDCl3) of compound 6l. 
Infrared spectrum (Thin Film, NaCl) of compound 6l. 
S157  
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-ethylundec-2-enoate (6m)     












































 13C NMR (126 MHz, CDCl3) of compound 6m. 
Infrared spectrum (Thin Film, NaCl) of compound 6m. 
S159  
 
Methyl (S,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-(3-phenylpropyl)undec-2-enoate (6n)      














































 13C NMR (126 MHz, CDCl3) of compound 6n. 
Infrared spectrum (Thin Film, NaCl) of compound 6n. 
S161  
 
Methyl (R,E)-5-ethyl-5-(2-oxooxazolidine-3-carbonyl)non-2-enoate (6o)    










































 13C NMR (126 MHz, CDCl3) of compound 6o. 
Infrared spectrum (Thin Film, NaCl) of compound 6o. 
S163  
 
Methyl (R,E)-5-ethyl-5-(2-oxooxazolidine-3-carbonyl)undec-2-enoate (6p)      














































 13C NMR (126 MHz, CDCl3) of compound 6p. 
Infrared spectrum (Thin Film, NaCl) of compound 6p 
S165  
 
(S)-N-Benzyl-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-methylpent-4-enamide (S11)  














































 13C NMR (126 MHz, CDCl3) of compound S11. 
Infrared spectrum (Thin Film, NaCl) of compound S11. 
S167  
 
(S)-N-Benzyl-2-(2-hydroxyethyl)-2-methylpent-4-enamide (S12)        














































 13C NMR (126 MHz, CDCl3) of compound S12. 
Infrared spectrum (Thin Film, NaCl) of compound S12. 
S169  
 
(S)-3-Allyl-1-benzyl-3-methylpyrrolidin-2-one ((S)-8)        













































 13C NMR (126 MHz, CDCl3) of compound 8. 
Infrared spectrum (Thin Film, NaCl) of compound 8. 
S171  
 
(R)-3-Allyl-3-methylpyrrolidin-2-one (S13)        














































 13C NMR (126 MHz, CDCl3) of compound S13. 
Infrared spectrum (Thin Film, NaCl) of compound S13. 
